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ABSTRACT
3D bioprinting combines emerging 3D printing technologies with
synthetic biology. The promise of 3D bioprinting technology is to fabricate
organs for transplantation, treat burn victims with in vivo skin repair, and
create wearable microbiomes. 3D bioprinting can successively build,
repair, or reproduce living human cells. This capability challenges eligible
subject matter doctrine in U.S. patent law because the law has no brightline standard for patent eligibility for nature-based products. As 3D
bioprinting technologies mature, U.S. patent law will need to respond to
situations where living and nonliving worlds merge. This Article proposes
a “Mixed-Scanned-Transformed” standard to supplement U.S. patent
law’s “markedly different characteristics” examination of nature-based
products. The markedly different standard arose from the Chakrabarty
case in 1980 and is most recently informed by the Myriad case in 2013,
but neither case involved merging living and nonliving worlds. By
applying this newly proposed standard, 3D bioprinted materials would
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Scanned-Transformed” standard and proposed clarity on what is not a
“human organism” will allow U.S. patent law to become more bright-line
towards 3D bioprinting inventions.
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INTRODUCTION
The 3D printing revolution has moved beyond consumer and
industrial uses and into biotechnology. This new technology produces
living biological cells, tissues, and organs by clicking a computer mouse.
Just as digitization of physical objects has enabled rapid production of
customized objects,1 the confluence of tissue engineering, synthetic
biology, and additive manufacturing can yield tailor-designed biomaterials
and organs. This new technology applies 3D printing’s ability to modify
virtual physical objects in digital computer-aided design (CAD) files
towards translating medical images of human anatomy into print-ready
Bio-CAD files. This new phenomenon is termed 3D bioprinting.
3D printing has blurred the line between the digital and physical
worlds.2 3D bioprinting as a subset of 3D printing similarly blurs the
digital and physical and also blurs the line between living and nonliving
worlds. As 3D bioprinting has emerged from the research laboratory and
into a commercial reality,3 it is eroding the boundaries separating human
from nonhuman and products of nature from printed products of nature.
These boundaries are fuzzy and inadequately defined. The transformative
technology of 3D bioprinting magnifies the unclear patentable subject
matter boundaries of biotechnology. The convergence of living and
nonliving worlds with the emergence of 3D bioprinting requires assessing

1. Deven R. Desai & Gerard N. Magliocca, Patents, Meet Napster: 3D Printing and the
Digitization of Things, 102 GEO. L.J. 1691, 1697–99 (2014).
2. See generally Daniel Harris Brean, Patenting Physibles: A Fresh Perspective for Claiming
3D-Printable Products, 55 SANTA CLARA L. REV. 837 (2015); Lucas S. Osborn, Regulating ThreeDimensional Printing: The Converging Worlds of Bits and Atoms, 51 SAN DIEGO L. REV. 553, 558–
62 (2014) (discussing that the advent of computer technology and developments in 3D printing
technology create struggles with how to apply the law of atoms to the computer world of “bits” of
ones and zeros).
3. CHRISTOPHER BARNATT, 3D PRINTING 177–84 (2d ed. 2014).
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what defines the patentable subject matter boundaries and the legal
standards that determine what can enter those boundaries.
This Article represents a proposal for evaluating the limits of
patentable subject matter necessitated by 3D bioprinting technology under
U.S. patent law. The emerging phenomena of 3D bioprinting challenges
the dividing line between living and nonliving and necessitates that the
patent system respond to better define patentable subject matter
boundaries. This Article fills a gap in legal scholarship by addressing how
3D bioprinting stresses patentable subject matter doctrine. To date, legal
scholars have assumed that the same assessment for 3D printing applies to
3D bioprinting. This Article challenges that assumption by demonstrating
that the long-standing uncertainties in the law of patentable subject matter
with biotechnological inventions4 are further stressed with the emergence
of 3D bioprinting technology and its applications. This Article’s guiding
theme is that a clearer standard will lead to clearer patenting in 3D
bioprinting.
This Article explores the ways that the U.S. patent system will need
to respond to the advent of 3D bioprinting. It proceeds as follows: after
introducing an overview of 3D printing, Part I describes the foundational
principles of 3D bioprinting technology and gives examples of
applications. This Part introduces Bio-CAD files that can translate medical
images into digital models, can modify living elements in silico, or can
introduce nonliving elements with living elements in silico.
Part II of this Article suggests a lack of a clear standard for patentable
subject matter in biotechnology through analyses of cases, United States
Patent & Trademark Office (USPTO) examination guidance, and
discussion of patent law in the Leahy-Smith America Invents Act (AIA).
Beginning with the early U.S. patent law cases concerning the nature and
non-nature distinction, Part II discusses decades of U.S. Supreme Court
and Federal Circuit cases that entangled patentable subject matter in
uncertainty. More specifically, it introduces the origins of the markedly
different characteristics standard, which serves as the current foundation
for USPTO examination of nature based products. Part II concludes with
an analysis of the statutory construction and legislative history of the
AIA’s vague phrase “human organism,” which obfuscates patentable
subject matter of nature based products.
Part III applies the markedly different characteristics standard and
the human organism exception to each facet of 3D bioprinting. It
concludes that processed 3D bioprinted materials would likely be
patentable subject matter. It determines that post-processed and integrated
4. Dan L. Burk, Dolly and Alice, 2 J. L. & BIOSCI. 606 (2015).
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3D bioprinted materials may or may not be patentable subject matter
depending on the reach of the human organism exception. It suggests that
3D bioprinting inventions can sidestep the human organism limitation
when the 3D bioprinted object is not fully biological but is either a mix of
biological and artificial elements or is a modified replica of a product of
nature. Part III also addresses why certain 3D bioprinting inventions that
merge living and nonliving elements are not patentable subject matter. It
investigates the following questions: Should a slightly modified
replication of a living tissue become patent eligible when it is 3D
bioprinted in a less than fully living state? What does it mean to be
“human” within 3D bioprinting? How does patent law doctrine address a
mixed biological–mechanical 3D bioprinted object? Should 3D bioprinted
wearable microbiomes that nourish the skin and repair damaged tissues be
considered patentable subject matter? Where does the notion of 3D
bioprinting stop, and where does the nonliving, mechanical world begin?
Part IV examines how patent law can respond to the need to have a
clearer standard for patentable subject matter with the emergence of 3D
bioprinting. Unless a more bright-line standard is provided, questions on
patent eligibility will abound as 3D bioprinting proliferates. In responding
to the impact of 3D bioprinting on patent law, this Article proposes a novel
claim: Because 3D bioprinting is rapidly evolving towards fusing living
and nonliving worlds, a more bright-line standard is needed to overcome
the shortcomings of the markedly different characteristics standard. This
Part suggests a “Mixed-Scanned-Transformed” (MST) standard to
supplement patent law’s markedly different characteristics examination of
nature-based products. This Part addresses fitting the proposed MST
standard within patent law’s uniformity principle. Part IV concludes with
policy implications of a clearer standard for patentable subject matter. It
argues that a more bright-line standard for patentable subject matter would
lead to clearer patenting, provide greater investment impetus, and reduce
downstream litigation burdens with emerging 3D bioprinting.
I.

OVERVIEW OF 3D BIOPRINTING

3D bioprinting combines synthetic biology with 3D printing in a
synergistic way to automate generation of living cells.5 3D bioprinting is
a subset of 3D printing, and pairs concepts of 3D printing with synthetic

5. Mark A. Lemley, IP in a World Without Scarcity, 90 N.Y.U. L. REV. 460, 478 (2015); Phoebe
H. Li, 3D Bioprinting Technologies: Patents, Innovation, and Access, 6 L. INNOVATION & TECH. 282
(2015); Timo Minssen & Marc Mimler, Patenting Bioprinting-Technologies in the US and Europe:
The 5th Element in the 3rd Dimension, in 3D PRINTING, INTELLECTUAL PROPERTY & INNOVATION –
INSIGHTS FROM LAW AND TECHNOLOGY (Rosa Maria Ballardini et al. eds., 2017).
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biology to produce biological materials.6 3D bioprinting refers to the
extrusion of a biological ink layer-by-layer,7 such that simultaneously
deposited live cells and growth factors produce a construction to grow
human cells or tissues.8
The same technological foundations of 3D printing apply to 3D
bioprinting. The novelty in 3D bioprinting is the printed product is
biological in nature, comprised of complex tissues, and has natural
architecture. The benefits of 3D bioprinting are the provision of real time
potential healthcare treatments, the measuring of efficacy and safety, and
the creation of more natural, cell-to-cell interactions compared to
traditional 2D printing methods.9
However, unlike 3D printing, where materials are easier to print and
the printers are rapidly being adopted by the masses,10 3D bioprinting
advancements have been severely limited by printable biological materials
that do not yet fully mimic nature.11 The successful future of 3D
bioprinting depends on optimizing the biomaterial properties so that
printed cells can remain viable for extended time periods to properly
organize and function.12
A.

Overview of 3D Printing

3D printing is a technology that enables the creation and replication
of a three-dimensional, solid object.13 3D printing utilizes an “additive
6. Jasper L. Tran, To Bioprint or Not To Bioprint, 17 N.C. J. L. & TECH. 123, 129 (2015).
7. Adam E. Jakus et al., Advancing the Field of 3D Biomaterial Printing, BIOMED. MATER.,
January 8, 2016, at 1.
8. Vivian K. Lee et al., 3D Bioprinting and 3D Imaging for Stem Cell Engineering, in
BIOPRINTING IN REGENERATIVE MEDICINE 33 (Kursad Turksen ed., 2015).
9. David Sher, The Top 15 Bioprinters, 3D PRINTING INDUSTRY (Aug. 26, 2015),
https://3dprintingindustry.com/news/top-10-bioprinters-55699/ [https://perma.cc/VU85-4VSX].
10. Stratasys Direct Manufacturing, 3D Printing Materials: Choosing the Right Material for Your
Application
3
(2015)
(unpublished
white
paper),
https://www.stratasysdirect.com/content/white_papers/STR_7463_15_SDM_WP_3D_MATERIALS
.PDF [https://perma.cc/6N7P-WW4L] (stating that 3D printing materials achievements have
skyrocketed over the last five to ten years and that 3D printing processes today can create prototypes
and end-use production parts in hundreds of plastic and metal materials).
11. Helena N. Chia & Benjamin M. Wu., Recent Advances in 3D Printing of Biomaterials, J.
BIOLOGICAL ENGINEERING, Mar. 1, 2015, at 2–3 (clarifying that advances in 3D printing machine
capabilities have not yet translated completely with biomaterials but suggesting that advances in
digitized medical imaging data and integration with patient-specific medical imaging data with 3D
printing will allow for printing of tissue engineering grafts that will match precisely a patient’s
contours).
12. See Jakus et al., supra note 7, at 5 (discussing that developments in 3D bioprinting materials
have been limited by tunability, or the ability to effectively change the formulation and properties of
the biological material, and printability, or the ability to consistently 3D print a material in a defined,
multi-layer construct).
13. Tabrez Y. Ebrahim, 3D Printing: Digital Infringement and Digital Regulation, 14 NW. J.
TECH. & INTELL. PROP. 37, 42 (2016).
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manufacturing” process to build products by adding many very thin layers
of material, layer on top of layer.14 Each layer produced by an additive
manufacturing process is, therefore, a cross-section of a part. The content
of the deposited material is built on top of the preceding layer and fused
to the underlying layer until an entire object emerges at the end of the
process.15
The brain of a 3D printing operation is an electronic CAD file, which
serves as a blueprint model for producing the output product.16 This CAD
file can be created from 3D modeling software, from scanning a 3D object,
or from tweaking a scanned object in modeling software. 3D printing
offers the ability to make a physical object using an electronic file, which
contains the digital printing instructions. In essence, a 3D printing machine
enables users to turn a digital blueprint into a physical object with the press
of a button.17
B.

Technological Foundations of 3D Bioprinting

3D printing is a technology that has been in existence since the
1980s, but 3D bioprinting is just beginning to emerge from the research
laboratory and into the marketplace.18 Just like a 3D printer can print a
physical object based on a digital CAD file,19 a 3D bioprinter can print
three-dimensional biological materials.20 3D bioprinting combines the
engineering principle of rapid prototyping with the science of tissue
engineering in a controlled environment to accelerate cell adhesion,

14. Elizabeth Matias & Bharat Rao, 3D Printing: On Its Historical Evolution and the Implication
for Business, 2015 PROCEEDINGS OF PICMET ‘15: MGMT. OF THE TECH. AGE 551, 551 (2015).
15. See Osborn, supra note 2, at 559.
16. Michael Weinberg, It Will Be Awesome if They Don’t Screw Up: 3D Printing, Intellectual
Property, and the Fight Over the Next Great Disruptive Technology 3–4 (Nov. 2010) (unpublished
white paper), https://www.publicknowledge.org/files/docs/3DPrintingPaperPublicKnowledge.pdf
[https://perma.cc/5EY2-P7FH] (explaining that the CAD design process eliminates the need to design
physical prototypes out of other materials not needed for the object, and that a designer can use a CAD
program to create and manipulate a virtual model that is saved to a file).
17. Id.
18. See BARNATT, supra note 3, at 19.
19. Lucas Osborn & Timothy R. Holbrook, Digital Patent Infringement in an Era of 3D Printing,
48 U.C. DAVIS L. REV. 1319, 1329 (2015) (discussing that 3D printing builds an object up layer-bylayer using a print head that emits a molten material to print a first layer, after which the print head
moves up to place the second layer upon the first layer, continuing the process until the object is
complete; further defining that a three-dimensional print requires instructions to a 3D printer in the
form of a CAD file, which is a digital representation of the physical object and can be created either
from scratch using a computer program or by scanning a physical object with a scanner).
20. Gabriela I. Coman, 3-D Bioprinting: 5 Things Medical Device Cos. Should Know, LAW360
(Feb. 18, 2016), https://www.law360.com/articles/760558/3-d-bioprinting-5-things-medical-devicecos-should-know [https://perma.cc/C4SF-XQ34].
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proliferation, and differentiation to produce functional, living tissues.21 3D
bioprinting’s ability to produce biological tissues and organs subject it to
a higher scrutiny than 3D printing.22 Another difference from 3D printing
is that 3D bioprinting processes are more complex, take greater time to
complete, and require more steps. For each of these reasons, the overview
of 3D bioprinting technology will be more in-depth than the overview of
3D printing technology.
3D bioprinting beneficially impacts healthcare through implantable
and non-implantable medical devices and cost-effective customizable
devices in three new ways.23 First, 3D bioprinting enables computercontrolled manufacturing24 of living human tissue through layered
deposition of material.25 Second, 3D bioprinting promotes nature’s magic
by fusing together biological cells during the 3D bioprinting process.26
Third, 3D bioprinting can combine nonliving materials with living
materials in bio-inspired printing processes to produce functional devices
in a customized fashion,27 which can also be used in non-healthcare
applications.
21. Silke Wust et al., Controlled Positioning of Cells in Biomaterials: Approaches Toward 3D
Tissue Printing, 2 J. FUNCT. BIOMATER. 119, 121–44 (2011) (defining 3D bioprinting as the
production of complex living and non-living biological products by placing proteins, peptides, DNA,
cells, hormones, or ECM molecules together with biomaterials through seeding cells onto scaffolds or
encapsulating cells into porous hydrogels for nutrient support to replicate living structures to
nanostructure scale).
22. See Tran, supra note 6, at 147–50.
23. CELESTE A. LETOURNEAU ET AL., 3D PRINTING OF MEDICAL DEVICES: WHEN A NOVEL
TECHNOLOGY MEETS TRADITIONAL LEGAL PRINCIPLES 4 (Colleen Davies et al. eds., 1st ed., 2015).
24. David Chimene et al., Advanced Bioinks for 3D Printing: A Materials Science Perspective,
44 ANNALS OF BIOMEDICAL ENGINEERING 2091 (2016).
25. Ali Bakshinejad & Roshan M. D’Souza, A Brief Comparison Between Available Bio-printing
Methods,
GREAT
LAKE
BIOMEDICAL
CONFERENCE
(Feb.
17,
2015),
https://pdfs.semanticscholar.org/f9cb/1d43990f14eaf6f3a9ed632b432cd050a05c.pdf
[https://perma.cc/3TRM-EDAN] (categorizing the biological aspect of 3D bioprinting either as: 1)
scaffold based printing, where a skeleton of organ/tissue geometry is printed using biomaterials, the
scaffold is subsequently populated with living cells to colonize the scaffold, and finally the scaffold
resolves into the system, or 2) scaffold-free printing, where the living cells are deposited directly into
the substrate, resulting in automatically generated structures through cell signaling; further describing
the bioprinting process itself as either being: 1) laser-assisted bioprinting, where a focused laser pulse
causes local vaporization of an energy absorbing layer, resulting in a bioink droplet based on the
energy of the pulse, or 2) laser-free bioprinting, where inkjet printing of a bioink occurs through
actuating a printhead either thermally or piezoelectrically, or alternatively through a robotic dispensing
mechanism resulting in a continuous stream of bioink).
26. See BARNATT, supra note 3, at 179–81; Lydialyle Gibson, Building Towards a Kidney,
HARVARD MAGAZINE, Jan.–Feb. 2017, at 38, 40–41 (describing the use of 3D bioprinting technology
to lay the foundation of a biological building block in the form of subcomponent of a nephron that
serves as a modular unit towards creating multi-layer tissue, which can be applied towards screening
of new drugs).
27. Neri Oxman, Variable Property Rapid Prototyping, 6 VIRTUAL & PHYSICAL PROTOTYPING
3, 8–13 (2011) (demonstrating Variable Property Modeling to 3D print bio-inspired natural structures
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Simply put, the 3D bioprinting process includes modeling and design
of blueprint instructions, depositing material by printing, and maturing of
the biological material with potential implantation. The process of 3D
bioprinting is comprised of three steps: First, a computer model or a
scanned image creates a digital blueprint of the object to be printed on the
computer; second, living cells are mixed with a gel to create bio-inks for
the 3D bioprinter; and third, the 3D bioprinter deposits the bio-ink through
printing nozzles onto a platform to produce the final product.28 In effect,
the three steps of 3D bioprinting can be characterized as pre-processing or
development of blueprints of organs, processing or actual organ printing,
and post-processing or accelerated organ maturation.29
In the first 3D bioprinting step, pre-processing, neuroimaging by
either magnetic resonance imaging (MRI) or computed tomography (CT)
converts medical imaging data into virtual 3D models of internal organs,
which can be edited in a 3D modeling program.30 The mapping of a human
organ via MRI or CT scan converts a medical image into a bio-computer
aided design (Bio-CAD) file, which allows for visualization of anatomic
structures, differentiation of tissue types, and generation of a
computational tissue model.31 The Bio-CAD file, which is the starting
point for 3D bioprinting, creates or modifies a software representation of
anatomic and geometric information of the 3D bioprinted tissue or organ.32
Bio-CAD files can also make it easy for the viewer to visualize a 3D
bioprinted object for use in a medical application or procedure.33
with graduated and varied properties by use of organic, inorganic, or multifunctional composites, such
as shells, pearls, corals, teeth, wood, silk, horn, collagen, and muscle fibers, for use in industrial and
architectural applications).
28. Craig C. Martin & Sara Tonnies Horton, Patent Eligibility of 3D Printed Organs Will Soon
Be an Issue, TODAY’S GENERAL COUNSEL, June–July 2014, at 36.
29. Vladimir Mironov et al., Organ Printing: Computer-Aided Jet-Based 3D Tissue Engineering,
22 TRENDS IN BIOTECH. 157 (2004) (describing that preprocessing primarily deals with the
development of a Computer-Aided Design, or CAD, blueprint files of a specific organ, processing
refers to actual CAD-printing or layer-by-layer placement of the cells or cell aggregates, and
postprocessing concerns the perfusion of printed organs and their biomechanical conditioning to
accelerate organ maturation; further predicting that developments with such steps and with 3D
bioprinting will yield, in the 21st century, cell and organ 3D bioprinters that are as broadly used as
biomedical research tools, as was the electron microscope in the 20th century).
30. Jason S. Naftulin et al., Streamlined, Inexpensive 3D Printing of the Brain and Skull, PLOS
ONE, 2015.
31. Ahmed Munaz et al., Three-Dimensional Printing of Biological Matters, in JOURNAL OF
SCIENCE: ADVANCED MATERIALS AND DEVICES 1, 2 (2016).
32. W. Sun et al., Bio-CAD Modeling and Its Applications in Computer-Aided Tissue
Engineering, 37 COMPUTER-AIDED DESIGN 1110, 1112 (2005).
33. 3D Prints in Medicine, U.S. DEP’T OF HEALTH AND HUM. SERVICES – NAT’L INST. OF
HEALTH: NIH 3D PRINT EXCHANGE, http://3dprint.nih.gov/about/medicine [https://perma.cc/TYV56LXX] (promoting itself as a trusted digital repository of digital 3D models for medical applications
that are compatible with 3D printers in its Terms & Conditions).
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In the second 3D bioprinting step, processing, spheroids of living
cells are dispensed by the 3D bioprinting and deposited layer-by-layer
onto hydrogels, which act like a biopaper to collect and maintain cell
placement, and aid in tissue fusion and maturation.34 The conceptual
framework for the processing step of 3D bioprinting is that spheroids will
be precisely dispensed onto specified hydrogel biopapers, such that tissues
and organs will eventually self-assemble and self-organize by perfusion.35
The ability to replicate nature inside of a 3D bioprinter challenges the
analysis of natural processes, products of nature, and transformations from
nature in U.S. patent law.
In the third 3D bioprinting step, post-processing, 3D bioprinted tissue
spheroids fuse by assembling, compacting, and maturing into functional
tissue.36 The post-processing step includes placing the 3D bioprinted
structure into an incubator for maturation, testing, monitoring, and
preservation.37 The ability to replicate nature during 3D bioprinting
maturation processes raises concerns under U.S. patent law concerning
transformations from nature.
C.

Applications: Organ Transplantation, In Vivo Skin Repair,
Wearable Microbiomes

3D bioprinting technology is capable of fabricating tissues in vitro or
in situ, and researchers have produced 3D bioprinted aortic valves, bones,
cartilage, ears, eyes, heart tissue, kidneys, skin, windpipes, and
vasculature.38 An emerging research application of 3D bioprinting is the

34. Natalie M. Kerestes, Bioprinting: Is This the Solution to the Organ Transplant Crisis?, U.
Paper 534 at 9 (2012).
35. Vladimir Mironov et al., Organ Printing: Tissue Spheroids as Building Blocks, 30
BIOMATERIALS 2164 (2009) (suggesting that self-assembled tissue spheroids are an alternative to
scaffold-based tissue engineering and, therefore, permit automation, scalability, reproducibility,
precision, and high cell density).
36. Rodrigo A. Rezende et al., Three-Dimensional Bioprinting of Human Organs: Phases and
Concepts, CONGRESSO LATINO AMERICANO DE ÓRGAOS ARTIFICIAIS E BIOMATERIAIS, Aug. 2015.
37. Armando Salim Munoz-Abraham et al., 3D Printing of Organs for Transplantation: Where
Are We and Where Are We Heading?, 3 CURR. TRANSPL. REP. 9, 96 (2016); Rodrigo A. Rezende et
al., Development of a Bioreactor by Computational Fluid Dynamics Simulations for the Maturation
of 3D Printed Organs by Rapid Prototyping, 32 CHEMICAL ENGINEERING TRANSACTIONS 1153
(2013).
38. See, e.g., Sean V. Murphy & Anthony Atala, 3D Bioprinting of Tissues & Organs, 32
NATURE BIOTECH. 773 (2014); Evan R. Youngstrom, 3D Printing and Healthcare: Will Laws,
Lawyers, and Companies Stand in the Way of Patient Care?, 6 PACE. INTELL. PROP. SPORTS. & ENT.
L.F. 91 (2016). In molecular and cellular biology, in situ is the intermediate classification between in
vivo and in vitro. In vivo means investigating something within its living context and in vitro refers to
something taken out of its context, whereas in situ refers to looking at something in its natural context
but perhaps not under natural conditions. In sum, in vivo means “in the living” and in situ means “on
site.”
OF TOLEDO MASTERS AND DOCTORAL PROJECTS,
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production of bioprosthetic ovaries.39 This Article focuses on three
applications of 3D bioprinting—organ transplantation, in vivo skin repair,
and wearable microbiomes—and how each can challenge patentable
subject matter principles.
One application of 3D bioprinting is organ transplantation. 3D
bioprinting utilizes tissue engineering principles to replace damaged
tissues, restore malfunctioning organs, and permit full organ
transplantation by mimicking native tissues.40 The application of 3D
bioprinting towards producing tissues and organs involves either the use
of a particular patient’s own cells or implantation of 3D bioprinted
materials to help regenerate organs.41 Organ fabrication via 3D bioprinting
is becoming a commercial substitute to address the organ donation
shortage in the U.S. 42 For example, 3D bioprinting research and
development is progressing towards the first replacement heart developed
from a patient’s own cells.43 3D bioprinting promises to decrease the
number of patients left waiting for organ transplants, reduce the number
of deaths due to organ inaccessibility, and eradicate organ rejection and
immunosuppression drugs, thereby revolutionizing medicine.44
Another application of 3D bioprinting is in vivo skin repair. 3D
bioprinting can be utilized for skin repair, skin substitution, and skin
reengineering, so that the 3D bioprinted skin equivalents can rapidly and
completely restore skin function.45 While still in its infancy, in situ 3D
bioprinting can form skin with properties similar to healthy skin, and can
39. See generally Monica M. Laronda et al., A Bioprosthetic Ovary Created Using 3D Printed
Microporous Scaffolds Restores Ovarian Function in Sterilized Mice, NATURE COMM., 2017
(discussing research aimed at creating functional 3D bioprinted replacement ovaries to help restore
fertility in women cancer survivors).
40. Amer B. Dabahneh & Ibrahim T. Ozbolat, Bioprinting Technology: A Current State-of-theArt Review, 136 J. OF MANUFACTURING SCI. & ENGINEERING 061016-1 (2014) (describing that 3D
bioprinting produces human organs by patterning and assembling living and nonliving materials with
a prescribed layer-by-layer stacking organization).
41. Anthony Atala, Printing a Human Kidney, TEDTALKS (Mar. 2011),
https://www.ted.com/talks/anthony_atala_printing_a_human_kidney?language=en [https://perma.cc/
MUY5-VZ6F].
42. MICHELLE GOODWIN, BLACK MARKETS: THE SUPPLY AND DEMAND OF BODY PARTS 7, 40–
41 (2006) (stating that each day, eighteen people on an organ waitlist die before ever receiving the
anticipated organ and are replaced with 110 persons will enter that list by end of the day, and that this
list continues to rise each year; further suggesting that while the demand drastically overshadows
supply, not all organ donations are viable because an organ donation does not always translate into a
successful organ transplant); Jeremy Thomas Harbaugh, Do You Own Your 3D Bioprinted Body?
Analyzing Property Issues at the Intersection of Digital Information and Biology, 41 AM. J. L. &
ETHICS 168, 173 (2015) (describing a current waiting list of near 125,000 in the U.S).
43. Cindy Glass, 3D-Printed Organs Are a Heartbeat Closer to Reality, AUTODESK (June 20,
2015), https://lineshapespace.com/3d-printed-organs-bioficial-heart/ [https://perma.cc/2353-D7SS].
44. See Kerestes, supra note 34, at 12–13.
45. Deepti Singh et al., 3D Printing of Scaffold for Cells Delivery: Advances in Skin Tissue
Engineering, POLYMER, 2016, at 4, 8–13.
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treat skin lesions and heal wounds.46 3D bioprinting techniques can treat
burn victims as an in vivo alternative to skin grafts, or can offer cosmetic
face printing to mimic celebrities’ faces, re-bioprinting one’s younger self
to appear perpetually young or replacing unwanted layers of flesh.47 3D
bioprinting has attracted interest from the skincare industry, including two
major commercialization partnerships.48 The L’Oreal-Organovo
partnership aims to develop 3D bioprinted skin tissues49 and develop
automated testing of cosmetic skin products.50 The BASF-Poietis
partnership proposes to 3D bioprint the closest equivalent to the original
physiological tissue of human skin and in doing so, support the
development and testing of cosmetic bioactives for skin care
applications.51 Moreover, consumer-goods giant Procter & Gamble has
invested in 3D bioprinting artificial skin research and development,
manufacturing, and test programs to test the efficacy and toxicity of its
new cosmetic, beauty, dermatology, and skin care products.52
Yet another application for 3D bioprinting is wearable microbiomes.
In addition to healthcare benefits, 3D bioprinting has clothing applications
in the form of wearable microbiomes, which can also support, control, and
manipulate living organisms in wearable clothing designs.53 Inspired by
nature, wearable microbiomes are produced by 3D bioprinted, wearable
natural materials that incorporate and contain living organisms in close
46. Rúben F. Pereira et al., Advanced Biofabrication Strategies for Skin Regeneration and
Repair, NANOMEDICINE, 2013, at 12–14.
47. See BARNATT, supra note 3, at 190, 194–96.
48. Andy Extance, Cosmetics Deals Push Skin 3D Bioprinting, CHEMISTRY WORLD (Sept. 24,
2015),
https://www.chemistryworld.com/news/cosmetics-deals-push-skin-3dbioprinting/8977.article [https://perma.cc/HY3G-995W]; BASF and Poietis Sign a Research and
Development Agreement on 3D Bioprinting Technology for Advanced Skin Care Applications, BASF
(July 10, 2015), https://www.basf.com/en/company/news-and-media/news-releases/2015/07/p-15281.html [https://perma.cc/2353-D7SS]; L’Oreal USA Announces Research Partnership with
Organovo
to
Develop
3-D
Bioprinted
Skin,
ORGANOVO
(May
5,
2015),
http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-newsArticle&ID=2129344
[https://perma.cc/4S6R-8TZT].
49. Organovo Investor Presentation, ORGANOVO 21 (Nov. 2015), http://organovo.com/wpcontent/uploads/2015/11/Organovo-Investor-Presentation-1115.pdf [https://perma.cc/JQD4-7B29].
50. Caroline Winter, L’Oreal’s Plan to Start 3D Printing Human Skin, BLOOMBERG (May 18,
2015),
http://www.bloomberg.com/news/articles/2015-05-18/l-oreal-s-plan-to-start-3d-printinghuman-skin [https://perma.cc/52TH-3ZLG].
51. Simon Cosimo, BASF and Poietis Enter R&D Agreement for 3D Bioprinting and Skin Care,
3DERS (July 12, 2015), http://www.3ders.org/articles/20150712-basf-and-poietis-enter-rd-agreementfor-3d-bioprinting-and-skin-care.html [https://perma.cc/9ZPA-KRSZ].
52. Andrew McDougall, P&G Sets Off on 3D Bioprinted Skin Research Project, COSMETICS
DESIGN (June 3, 2015), http://www.cosmeticsdesign-europe.com/Formulation-Science/P-G-sets-offon-3D-bioprinted-skin-research-project [https://perma.cc/DLG8-FQAK].
53. Carrie Wyman, Neri Oxman’s 3D Printed Photosynthetic Wearables Shine New Light on
Art, Design, Science & Technology at TED2015, STRATASYS (May 13, 2015),
http://blog.stratasys.com/2015/05/13/neri-oxman-ted-2015/ [https://perma.cc/B9BN-Y6F5].
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proximity to skin in a symbiotic relationship ideal for new spacesuit
designs.54 This new 3D bioprinting application blurs the boundary
between nature and the human body, and contains functional materials that
can be tuned for mechanical and optical properties in order to interact with
the surrounding environment.55 By augmenting living human tissues with
additional living elements that make materials, wearable microbiomes can
continuously produce useful substances.56 The advent of 3D bioprinted
wearable microbiomes that nourish skin and repair damaged tissues is
challenging the notion of “mother nature” by imparting a living quality
into objects.57
II.

NO BRIGHT-LINE TEST FOR PATENTABLE SUBJECT MATTER IN
BIOTECHNOLOGY

3D bioprinting technology is a biotechnological innovation that
stresses the U.S. patent regime. As 3D bioprinting matures, patent law will
need to respond to a universe where the biological and mechanical worlds
will move closer together. Just as other biotechnologies have burgeoned
by supporting legal structures, 3D bioprinting presents another
biotechnological innovation that will require U.S. patent law to evolve in
order to create new products, healthcare solutions, and commerce.
One of the keys to enabling patenting activity in the emerging 3D
bioprinting industry will be to not exclude certain inventions from being
patent eligible. There has been a rich history of categorical exclusions by
courts, resulting in a non-cohesive and inconsistent precedent58 on
patentable subject matter, and highly subjective interpretations of qualities
of inventions being patentable subject matter. 59
54. Collin Jeffrey, World’s First Photosynthetic Living Matter-Infused 3D-Printed Wearable,
NEW ATLAS (May 18, 2015), http://newatlas.com/mushtari-3d-printed-photosynthetic-livingembedded-wearable/37548/ [https://perma.cc/S4TS-J6VQ].
55. David Sher, Neri Oxman Takes Us for a 3D Printed Polyjet Ride Into Astrobiological
Exploration, 3D PRINTING INDUSTRY (Nov. 26, 2014), https://3dprintingindustry.com/news/nerioxman-polyjet-skin-37099/ [https://perma.cc/SPY7-5ASX].
56.
Mediated
Matter:
Overview,
MIT
MEDIA
LAB,
https://www.media.mit.edu/research/groups/mediated-matter
[https://perma.cc/925C-7SXK]
(specifying that wearable microbiomes, which are produced by 3D bioprinting, are embed
photosynthetic microbes that convert sunlight into table sugar, which is then consumed by compatible
microbes and converted into materials such as scents, colors, pigments, and fuels); see also MIT Media
Lab Mediated Matter Group, Mushtari, VIMEO (2015), https://vimeo.com/131786000.
57. Neri Oxman, Towards a Material Ecology, WORLD ECON. F. (Jan. 17, 2016),
https://www.weforum.org/agenda/2016/01/towards-a-material-ecology/
[https://perma.cc/D9RW92DL].
58. Daniel J. Klein, The Integrity of Section 101: A “New and Useful” Test for Patentable Subject
Matter, 93 J. PAT. & TRADEMARK OFF. SOC’Y 287, 291 (2011).
59. The phrases “patentable subject matter” and “patent eligibility” are synonymous. However,
there is a distinction between “patentable subject matter” (being patent eligible) and “patentability,”
which refers to whether a patent application fulfills statutory requirements. Thus, “patentable subject
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The Federal Circuit has issued decisions that provide guidance on
patentable subject matter with biotechnological inventions, but there is no
bright-line standard for when an invention derived from a naturally
occurring product is considered patentable subject matter.60 There has
been a history of changes in U.S. patent law as to what biotechnological
inventions qualify as patent eligible subject matter.61 It is unclear as to
whether a biotechnological product produced by 3D bioprinting
technology would or would not be patentable subject matter.

matter” (being patent eligible) refers to belonging within a class of inventions for which a U.S. patent
may be sought whereas “patentability” refers to the ability to get a patent application issued after
satisfying 35 U.S.C. §§ 101 (utility), 102 (anticipation), 103 (non-obviousness), and 112 (enablement).
Thus, if a patent eligible invention is useful, novel, non-obvious, and adequately described in a patent
application, then the invention could be patentable if determined so by the USPTO. This means that
an invention can be patentable if it first is patent eligible subject matter and if it second also satisfies
the requirement in 35 U.S.C. §§ 101, 102, 103, and 112. In other words, patentable subject matter is
necessary but not sufficient to warrant patentability. An invention that includes patentable subject
matter is only potentially patentable, but whether a patent actually issues still turns on other statutory
requirements.
Moreover, a patent attorney or patent agent can inform a client that an invention is “patentable
subject matter” (patent eligible) because it qualifies as something for which one could apply for a
patent. However, a patent attorney or a patent agent may not inform a client whether an invention is
patentable because only the USPTO can make a determination after conducting a search and
examination, and assessing responses from the patent attorney or patent agent. Nonetheless, a patent
attorney or patent agent may conduct an independent search or provide a written opinion on the
patentability of an invention, but it should be noted that such a function is only an opinion, unlike a
patentability determination made by the USPTO.
60. The scope of this Article is limited to products, such as 3D bioprinted materials, which are
utilized for tissues and organs. This Article does not consider process or method claims specifically,
but acknowledges that materials or products produced by 3D bioprinting processes should be evaluated
for patentable subject matter. Thus, the Article’s emphasis is on whether 3D bioprinted materials are
eligible for or qualify for patent protection, regardless of the process used to produced them. A patentee
would be more interested in understanding patenting (or achieving issuance of a patent) of 3D
bioprinted end products more so than the processes used to create them; the reason is that a patentee
that chose only to pursue a method or a process patent claim could not prohibit a competitor from
patenting a different process to arrive at the same 3D bioprinted material. Thus, rather than focus on
the minimal protection afforded by process patent claims, this Article presupposes that product patent
claims are of more importance to a 3D bioprinting inventor. As a result, the analysis provided herein
is centered on 3D bioprinted materials that are captured in a product patent claim, and whether such a
drafted patent claim even qualifies as patentable subject matter.
61. The scope of this Article is limited to patentable subject matter for utility patents, which are
the majority of all issued U.S. patents. This Article does not consider plant patents, which are governed
by 35 U.S.C. § 161 and whose hallmark is “asexual” reproduction of the new plant “variety.” This
Article also does not consider design patents, which are governed by 35 U.S.C. § 171 and protect the
“new, original and ornamental design for an article of manufacture.” Also, while this Article discusses
3D bioprinted materials that may be utilized for medical applications, it does not delve in-depth into
inventions governed by 35 U.S.C. § 287(c), which concerns treatment from medical procedures, is
narrowly defined, and provides that there can be no remedy for a patent on certain medical or surgical
procedures.

2017]

3D Bioprinting

15

Regardless of whether one thinks 3D bioprinting inventions should
or should not be patent eligible,62 it is universally accepted that the notion
of patent eligibility is of great importance in affecting entire industries.
Moreover, patentable subject matter is deemed the gateway to
patentability, which has more rigorous requirements.63 Therefore, it is
critical to understand why, and in what aspects, biotechnological
inventions like 3D bioprinting challenge the boundaries of patent eligible
subject matter doctrine.
Patent eligibility continues to be an unsettled field. Advents in
emerging biotechnologies that seemingly utilize products of nature, such
as 3D bioprinting, have posed obstacles to the patent eligibility doctrine.
In order to understand the current state of how 3D bioprinting stresses
patent eligibility, it is helpful to know how history got us here. Also,
identifying any inconsistencies between the USPTO’s examination
procedures and court decisions on biotechnological inventions regarding
products of nature will help clarify the boundaries of patentable subject
matter.
A.

Overview of 35 U.S.C. § 101

Section 101 of the Patent Act governs which inventions may be
patented. According to 35 U.S.C. § 101, “whoever invents or discovers
any new and useful process, machine, manufacture, or composition of
matter, or any new and useful improvement thereof, may obtain a patent
therefor, subject to the conditions and requirements of this title.”64 It
provides that two criteria for subject matter eligibility must be satisfied:
(1) the invention must be directed to one of the four statutory categories
(process, machine, manufacture, or composition of matter) and (2) the
invention must not encompass a judicially recognized exception.65 Patent
practitioners draft patent claims66 for non-chemical formulation inventions
62. This Article does not discuss ethical and moral boundaries raised by advancements in
biotechnologies. For an in-depth discussion on whether patents should issue on morally controversial
inventions, such as with the use of embryonic stem cells, genetically modified transgenic animals, and
methods of cloning animals, please see Margo A. Bagley, Patent First, Ask Questions Later: Morality
and Biotechnology in Patent Law, 45 WM. & MARY L. REV. 469 (2003).
63. JANICE M. MUELLER, PATENT LAW 343 (4th ed. 2013).
64. 35 U.S.C. § 101 (2012).
65. U.S. PATENT AND TRADEMARK OFFICE, MANUAL OF PATENT EXAMINING PROCEDURE §
2106 I (9th ed. 2015) [hereinafter MPEP] (stating the non-limiting examples of claims that are not
directed to one of the statutory categories are: i. transitory forms of signal transmission, ii. a human
per se, iii. a legal contractual agreement between two parties, iv. a computer program, v. a company,
vi. a mere arrangement of printed matter, and vii. data per se; further specifying that judicially
recognized exceptions include laws of nature, natural phenomena, and abstract ideas).
66. The heart of a patent application or an issue patent is the patent claims, which set forth in
worth the metes and bounds of the invention. While legal scholars have debated the analogies between
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involving either a process, a product, or an improvement to an existing
product or process.67
A process is a series of steps that is not excluded as non-statutory
subject matter.68 In patent practice, a process is commonly termed
“methods,”69 and is a combination of steps that are manipulative.70 Process
inventions are typically divided into two types,71 either “a method of
making” or a “method of using.”72 For example, in 3D bioprinting, process
inventions can involve a treatment of materials,73 or a series of acts74 or
steps75 performed to produce a 3D bioprinted material, such as a method
of a 3D bioprinted living tissue or organ. Additionally, a process invention
for 3D bioprinting can involve a method of using the 3D bioprinted
material in a medical application, such as the earlier application examples
of in vivo skin repair and a wearable microbiome.
An invention on a product concerns tangible things (objects or
artifacts), which in terms of Section 101 consist of machines,
manufactures, or compositions of matter. A machine is a concrete thing
consisting of parts or devices.76 A machine’s novelty lies in its components
or the new ways in which the components are combined.77 A manufacture
is an article produced from raw or prepared materials and is a broadly
defined, residual category of manmade items.78 Composition of matter
includes chemical compounds, mechanical or physical mixtures, and

intellectual property conceptualization and real property, in effect, patent claims are akin to a legal
description of real estate identified in boundaries of a piece of land.
67. See generally John R. Thomas, Of Text, Technique and the Tangible: Drafting Patent Claims
Around Patent Rules, 17 J. MARSHALL J. COMPUTER & INFO L. 219 (1998).
68. Ex Parte Murray, 9 U.S.P.Q.2d 1819 (B.P.A.I. 1988).
69. Vita-Mix Corp. v. Basic Holding, Inc., 581 F.3d 1317, 1323 (Fed. Cir. 2009) (explaining that
the basic feature for method claims utilizes the preamble in defining the method in terms of the
fundamental purpose of the method).
70. JOHN GLADSTONE MILLS ET AL., PATENT LAW BASICS § 6:1 (2010).
71. While the distinction in process steps is a matter of characterization, in patent practice there
is not much of a substantive effect in such a division.
72. See In re Pleuddemann, 910 F.2d 823, 825–26 (Fed. Cir. 1990).
73. Cochrane v. Deener, 94 U.S. 780, 788 (1876) (“A process is a mode of treatment of certain
materials to produce a given result. It is an act, or a series of acts, performed upon the subject-matter
to be transformed and reduced to a different state or thing.”).
74. NTP, Inc. v. Research in Motion, Ltd., 418 F.3d 1282, 1316 (Fed. Cir. 2005) (quoting Minton
v. NASD, 336 F.3d 1371, 1378 (Fed. Cir. 2005)).
75. In re Kollar, 286 F.3d 1326, 1332 (Fed. Cir. 2002) (“A process . . . consists of a series of acts
or steps . . . . It consists of doing something, and therefore has to be carried out or performed.”).
76. Office of Patent Legal Administration, Evaluating Subject Matter Eligibility Under 35 U.S.C.
§ 101: August 2012 Update, U.S. PATENT AND TRADEMARK OFF. (2012),
https://www.uspto.gov/sites/default/files/patents/law/exam/101_training_aug2012.pdf
[https://perma.cc/WQ5K-6TM2].
77. MILLS, supra note 70, § 6:2.
78. Diamond v. Chakrabarty, 447 U.S. 303, 308 (1980).
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alloys.79 For example, tangible 3D bioprinting inventions can include the
3D bioprinter, the material outputted by the 3D bioprinter, the substance
produced after completion of all of the steps of 3D bioprinting, the
chemical formulation (or composition of matter) of the 3D bioprinted
material, or the mixture of mechanical and biological components
resulting from a 3D bioprinting process. Thus, as discussed in the earlier
application examples, 3D bioprinted materials, such as a living tissue for
organ transplantation, skin produced for in vivo treatment, or a wearable
microbiome, may be considered a tangible product in terms of Section 101.
In addition to obtaining inventions on processes and tangible
products, inventors can also obtain process patents on newly discovered
uses. Under the Patent Act, “a process can include a new use of a known
process, machine, manufacture, composition of matter, or method.”80 In
other words, an inventor can protect a newly discovered property of a
known product or newly discovered uses of a known process.81 For
example, as mentioned earlier with 3D bioprinting application examples,
a 3D bioprinted invention can protect newly discovered biological
properties of 3D bioprinted skin for new cosmetic testing purposes or a 3D
bioprinted wearable microbiome for new spacesuit designs. Moreover, a
3D bioprinting invention can protect a newly discovered use of known
steps of a 3D printing process, such as utilizing 3D printing processes for
in vivo skin treatment.
While not mentioned in the Patent Statute, the judicially-created82
product-by-process claim is another way to protect inventions, defining
the product by its method or process of construction.83 Product-by-process

79. Id.
80. 35 U.S.C. § 100(b) (2012).
81. However, such newly discovered properties or uses would still be subject to the proprietary
interests of others and must meet anticipation (or § 102) requirements. The point being made here is
not about patentability, but instead that newly discovered properties or newly discovered uses would
also be patent eligible subject matter.
82. Mark D. Passler, Product-By-Process Patent Claims: Majority of Court of Appeals for the
Federal Circuit Forgets the Purpose of the Patent Act, 49 U. MIAMI L. REV. 233, 235–40 (1994)
(describing the tortured history of the product-by-process claim where at first, courts recognized the
claims by describing the end product by the process of how it was produced, which began with the
1891 case of Ex Parte Painter that established the Necessity Rule, whereby product inventions could
be protected through process terms when process terms were the most accurate manner in which to
describe the invention).
83. MORGAN D. ROSENBERG, ESSENTIALS OF PATENT CLAIM DRAFTING (Matthew Bender ed.,
2016) (considering a product-by-process claim to be a hybrid of an apparatus claim and a method
claim, and as a composition of matter or article manufactured by a particular process; further
suggesting that product-by-process claims have long been interpreted only by a product produced by
the same process described in the claim, such that a product-by-process claim defines the product itself
and not the process and, therefore, an identical product made in a different manner than stated in the
claim would not infringe the product-by-process patent claim).
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patent claims are an alternative strategy84 for capturing the product by how
it is made.85 While narrower than a composition of matter claim86 and a
pure product claim,87 a product-by-process claim could protect a limited
set of 3D bioprinted materials that are described by a specific 3D
bioprinting process to make them.
U.S. patent law requires that a patent claim be directed to one of these
four patent eligible subject matter categories or be a product-by-process
patent claim. Patentable subject matter must fit within judicial limits
established by the Supreme Court and the Federal Circuit.88 If a patent
claim does not fit within one of these categories, then the patent claim will
not be patent eligible and would be considered non-statutory subject
matter.
B.

Products of Nature Are Not Patentable Subject Matter

A U.S. patent protects an invention based on human ingenuity but
not on something already existing in nature. The public domain of nature
is not patentable subject matter in U.S. patent law because it is for all of
humanity to share.89 Thus, it is important to draw boundaries to protect the
public domain from private property rights.
Nature-based products are not patentable subject matter, even when
they are newly discovered and brought to the public attention.90 The reason
for this is that the patent system is designed to incentivize and reward
inventive activity, and the discovery of preexisting items does not involve
human-created ingenuity or development. In effect, one who goes into
nature and simply brings a product of nature into the public domain does
not have a discovery worthy to be a patent.
84. Jason R. Strobel, Product-by-Process Claims: Product or Process Claims?, HAHN LOESER
(June 4, 2009), http://www.hahnlaw.com/experience/product-by-process-claims-product-or-processclaims-jason-r-strobel-esq [https://perma.cc/LH8D-SJ6N] (suggesting that product-by-process patent
claims are most frequently used in chemical and biological technology inventions for protecting
products with references to the process steps of its production only when the product cannot be defined
in any other way).
85. ROBERT C. FABER, LANDIS ON MECHANICS OF PATENT CLAIM DRAFTING §§ 5:2, 10:5 (5th
ed. 2008) (defining a product-by-process claim as one where an element of the article is claimed by
reciting the process for fabrication of the article or element by using a method claim or method
limitations for the process step in which the product or its elements are formed).
86. Id. § 6:1 (defining compositions of matter as products where the chemical nature of the
substance or material used is the distinguishing feature and utilizes a chemical element or compound).
87. Id. § 5:1 (defining an article of manufacture, or a product or apparatus, as a combination of
elements such that the elements are tied together in a mechanism or with the use of means-plusfunction clauses).
88. Laura Masterson, The Future of Medical Device Patents: Categorical Exclusion After Ebay,
Inc. v. Mercexchange, L.L.C., 20 B.U. J. SCI. & TECH. L. 274, 279 (2014).
89. Brief for Respondent at 5, Bilski v. Kappos, 561 U. S. 593 (2010).
90. MPEP, supra note 65, § 2105 II.A.4.
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Assuming this exemption for products of nature does not apply to a
certain 3D bioprinting invention, then 3D bioprinting inventions might fit
within multiple categories of patentable subject matter. In fact, it may
seem that nearly all 3D bioprinted inventions can fit into one of these
statutory categories, or the judicially-created product-by-process claim,
with some imagination and creativity. In general, the linguistic separation
between the statutory categories is nothing more than rhetorical divisions
for biotechnological inventions.91 Because clever patent claims drafting
will allow one to capture inventions to fit within one of these categories,92
the disconnect between the advent of 3D bioprinting and patent law is not
of statutory categorization.
Instead, what is critical for 3D bioprinting inventions is to determine
how far patent law can reach in determining what may be patentable
subject matter. Because 3D bioprinting increasingly blurs the line between
living and nonliving, and potentially between digital and physical worlds,
the patent system will need to react by redefining its standard for assessing
patentable subject matter. In order to redefine the standard, it helps to
understand how courts have assessed patentable subject matter and
attempted to define the breadth of what Section 101 allows.
C.

Biotechnology Decisions by the U.S. Supreme Court and Federal
Circuit Courts

What qualifies as patentable subject matter has been a source of
considerable debate since the inception of biotechnological applications.93
Early cases concerning products of nature in biotechnology patents
focused on biological purification processes to produce compounds. In the
1911 case Parke-Davis & Co. v. H.K. Mulford Co., the patent on purified
adrenaline created by structural differences from the natural form derived
from animal glands was upheld.94 Judge Learned Hand reasoned that
because the adrenaline was isolated and purified from its natural
surroundings, it was not a product of nature and was a new product both
commercially and therapeutically.95
Parke-Davis was the foundation of the product-of-nature question in
patent law, demonstrating the lack of a clear line between the natural and
91. See generally Dan L. Burk, The Problem of Process in Biotechnology, 43 HOUS. L. REV. 561
(2006–2007) (suggesting a great deal of trouble exists in distinguishing between product and process
inventions in biotechnology, and proposing that a new use of a product is already encompassed in the
product patent, even when entitled to a patent on the new process).
92. Tun-Jen Chiang, Fixing Patent Boundaries, 108 MICH. L. REV. 523, 537 (2010).
93. ROBERT A. BOHRER, A GUIDE TO BIOTECHNOLOGY LAW AND BUSINESS 77 (2007).
94. Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (C.C.S.D.N.Y. 1911).
95. Jacob S. Sherkow & Henry T. Greely, The History of Patenting Genetic Material, 49 ANN.
REV. GENET. 161, 164 (2015).
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non-natural in patent law.96 Following Parke-Davis, in 1931, the Supreme
Court in American Fruit Growers held that an orange dipped in a solution
of borax to render the skin mold resistant was not a manufactured article
and thus was not patentable.97 The decision considered whether the
addition of a chemical to a product of nature was a new use or property.
The Supreme Court held that the addition of borax to a rind of fruit only
protects the natural article and does not produce a new article with a
“distinctive form, quality, or property.”98 Thereafter, in 1938, the U.S.
Court of Customs and Patent Appeals held in In re Merz that a purified
substance that differed from that found in nature is patentable subject
matter.99
These early cases demonstrated that a product of nature that
undergoes a change from its state in nature, whether in encountering a
structural difference or being purified, would be patentable subject matter.
However, no case precisely defined what constituted a change from nature,
or whether purification was required to be a certain amount, degree, or
kind. The purification issue was revisited in Funk Brothers Seed Co. v.
Kalo Innoculant Co., which found that a specific combination of different
kinds of bacteria was not patent eligible because the invention covered the
aggregation of bacteria, which did not “create a state of inhibition or of
non-inhibition in the bacteria” and which was a quality that was “free to
all men.”100
Patents of modified products of nature for biotechnology
applications continued to be obtained in the 1950s and 1960s, and without
much controversy for decades after.101 Patents with a claim element of
“gene” and for “DNA” were issued in the 1970s.102 However, it remained
96. Christopher Beauchamp, Patenting Nature: A Problem of History, 16 STAN. TECH. L. REV.
257, 262–63 (2013) (summarizing that before Parker-Davis, patents concerning biological substances
merely extracted natural sources, and Parker-Davis provided a template for hormone patenting,
creating a gateway to patenting isolated biological structures).
97. American Fruit Growers, Inc. v. Brogdex Co., 283 U.S. 1, 11 (1931).
98. Id. at 11–12; see also In re Ewald, 129 F.2d 340, 342 (C.C.P.A. 1942) (holding that a cored
pear was not manufactured because it did not possess a new name, character, or use).
99. In re Merz, 97 F.2d 599, 601 (C.C.P.A. 1938) (assessing the outlines of the purification
doctrine by determining that while a patent on a method for producing a greater degree of purity than
what is produced by a former method is not patentable subject matter, there is an exception if the
process produces an article of purity that differs in kind and that may be patentable subject matter).
100. Funk Bros. Seed Co. v. Kalo Innoculant Co., 333 U.S. 127–30 (1948).
101. See Sherkow & Greely, supra note 95, at 164–65 (summarizing that successful patents were
attained for nucleotide derivatives throughout the 1950s and 1960s, including for synthesized
nucleotide polyphosphates in 1968, and for RNA and other increasingly complex products of
biological intervention).
102. Andrew W. Torrance, Synthesizing Law for Synthetic Biology, 11 MINN. J. L., SCI., & TECH.
629, 639 (2015) (specifying that for the first time in 1971, a patent with a claim element of “gene”
appeared in U.S. Patent No. 3,710,511, and a patent issued with “DNA” as a claim element in U.S.
Patent 3,755,086).
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generally understood that nonliving objects that were not changed from
their natural state were not patentable subject matter until the landmark
Diamond v. Chakrabarty decision.103
1.

The Landmark Chakrabarty Decision

In 1980, the Supreme Court encountered a biotechnology invention
that promoted changes from nature with the advent of gene-related
innovations. In Diamond v. Chakrabarty, the inventor made three types of
claims: first, a process claim for the method of producing bacterium;
second, claims for an inoculum that comprised a carrier material floating
on water, such as straw, and the new bacterium; and third, claims to the
bacterium itself.104
The patent claim directed at the oil-eating bacterium was rejected by
the USPTO as not constituting patentable subject matter because
bacterium was considered a: 1) product of nature and 2) living thing.105
However, the Supreme Court rejected these two grounds and found the
bacterium to be patentable subject matter because the bacterium was “a
nonnaturally occurring manufacture or composition of matter.”106 The
Supreme Court declared that “anything under the sun that is made by man”
was eligible for patent protection.107 The Supreme Court upheld the patent
because, unlike the bacterium in Funk Brothers, the bacterium was
manipulated nature. The Supreme Court widely interpreted the terms
“manufacture” and “composition” of matter in reasoning that the patent
claim directed to the bacterium was “a product of human ingenuity with a
distinctive name, character, and use.”108 The Supreme Court stated: “Here,
by contrast, the patentee has produced a new bacterium with markedly
different characteristics from any found in nature and one having the
potential for significant utility. His discovery is not nature’s handiwork,
but his own; accordingly, it is patentable subject matter under §101.”109
The “markedly different characteristics” language was not the test
utilized in Chakrabarty.110 Instead, “markedly different characteristics”
103. See Diamond v. Chakrabarty, 447 U.S. 303, 309–10 (1980).
104. U.S. Patent No. 4,259,444 (filed June 7, 1972) (specifying a human-made, genetically
engineered bacterium capable of breaking down multiple components of crude oil, and discussing that
such a property is possessed by no naturally occurring bacteria and is believed to have significant
value for the treatment of oil spills).
105. See Diamond, 447 U.S. at 309–10.
106. Id.
107. Id. at 309.
108. Id. at 309–10 (quoting Hartranft v. Wiegmann, 121 U.S. 609, 615 (1887)).
109. Id. at 310 (emphasis added).
110. Letter from Herbert C. Wamsley, Exec. Director, Intellectual Prop. Owners Ass’n, MayoMyriad
Guidance
to
USPTO
(July
31,
2014),
http://www.ipo.org/wpcontent/uploads/2014/08/Myriad.pdf [https://perma.cc/DLX4-TVEM].
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was an observation in the case that was later adopted as a standard by the
Federal Circuit for assessing patentable subject matter of genes in
Association for Molecular Pathology v. Myriad Genetics, Inc. (hereinafter
Myriad).111 The Supreme Court in Chakrabarty was not establishing
“markedly different characteristics” as a standard and it did not provide
additional support for what “markedly different” meant.
The consequence was an expansive approach to patent eligibility
with seemingly no patentable subject boundaries, which has spawned
significantly more investment in the biotechnology industry.112 The
Supreme Court’s reasoning in Chakrabarty reiterated that even though the
Supreme Court and the Federal Circuit had established the judicial limits
on what may be patentable subject matter, not every invention is embraced
only within statutory terms.113 In fact, Chakrabarty provided support that
the language of Section 101 was meant to be broad and not off-limits,
especially because technological advances are not foreseeable.114 The
central holding of Chakrabarty allowed life forms that encountered human
intervention to be a boon to the biotechnology industry.115 Chakrabarty
reinforced that Congress intended patent laws be given wide scope beyond
the time that technologies envisioned when the Patent Act was drafted.116
2.

Clarifying Markedly Different in the Myriad Decision

The markedly different characteristics standard was put to test in
Myriad, which involved a suit filed against Myriad Genetics, seeking to
invalidate their claims on isolated DNA on the grounds that the claims
covered unpatentable subject matter.117 The plaintiffs challenged that the
composition of matter claims that covered isolated DNA had retained the
same nucleotide sequence as native DNA and, therefore, were
unpatentable as a product of nature.118 The district court judge held the
111. Samantak Ghosh, Gene Patents: Balancing the Myriad Issues Concerning the Patenting of
Natural Products, 27 BERKELEY TECH. L.J. 241, 250 (2012); Ass’n for Molecular Pathology v. Myriad
Genetics, Inc., 653 F.3d 1329 (Fed. Cir. 2011).
112. K.K. SINGH, BIOTECHNOLOGY AND INTELLECTUAL PROPERTY RIGHTS: LEGAL AND SOCIAL
IMPLICATIONS 31 (2015).
113. See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
114. Id.
115. Rebecca S. Eisenberg, The Story of Diamond v. Chakrabarty, in INTELLECTUAL PROPERTY
STORIES 256–57 (Jane C. Ginsburg & Rochelle Cooper Dreyfuss eds., 2006); Robert Greene Sterne
& Lawrence B. Bugaisky, The Expansion of Statutory Subject Matter Under the 1952 Patent Act, 37
AKRON L. REV. 217, 223–23 (2004).
116. See Diamond, 447 U.S. at 308.
117. See generally Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F.
Supp. 2d 181 (S.D.N.Y. 2010), aff’d in part, rev’d in part, 653 F.3d 1334 (Fed. Cir. 2011).
118. Id. at 181–84 (discussing the composition of matter claims covering two “isolated” human
genes, BRCA1 and BRCA2, which were found to be associated with a predisposition for breast and
ovarian cancer).
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genes were unpatentable because they were not markedly different from
native DNA; purification alone did not change the essential characteristics
of nucleotide sequence of the DNA.119
On appeal, the U.S. Court of Appeals judges had differing opinions.
Judge Lourie found that isolated DNA was patentable subject matter and
“markedly different” because it was not covalently bonded to other genetic
material because it was cleaved from native DNA and synthesized to
consist of only a small fraction of a naturally occurring DNA molecule.120
Judge Lourie distinguished purification in Myriad from that of ParkeDavis by clarifying that isolated DNA was not purified DNA because
“purification makes pure what was the same material.”121 In other words,
Judge Lourie viewed that a product of nature became “markedly different”
through changes in “covalent bonding,” “cleaving,” and “synthesis,” as
long as the end result was not the same material.
In the concurring opinion, Judge Moore posited that “markedly
different” meant an enlargement of utility or a new utility.122 Unlike Judge
Lourie, who focused on the change in chemical structure as identifying
“markedly different characteristics,” Judge Moore felt that a change in
chemical structure was not enough to be considered “markedly different.”
Instead, Judge Moore suggested that a product of nature must be used in a
different way, which in science happens through exploiting either the
properties or the function of a material for a purpose.
By contrast, dissenting Judge Bryson found the gene and gene
fragments to be unpatentable subject matter because the structural changes
were merely “incidental to the extraction of the genes from nature” that
had “no other uses other than their native counterpart.”123 Judge Bryson’s
reasoning was that the isolated DNA was not a new use that differed from
its native use, but simply a consequence of possession that was similar to
extraction of minerals from the earth.124 In other words, Judge Bryson
viewed that a product of nature could not become “markedly different”
unless there was another use separate from possession.
In sum, the differing judges all agreed that a product that was
“markedly different” from nature was patentable subject matter. However,
they disagreed as to what was considered “markedly different.” Whereas
Judge Lourie focused on “markedly different” being a distinctive chemical
identity, Judge Moore focused on a new utility and not just a literal
119. Id. at 231–32.
120. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 653 F.3d 1329, 1351–52 (Fed. Cir.
2011).
121. Id.
122. Id. at 1364–67.
123. Id. at 1375–79.
124. Id. at 1375–78.
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chemical difference, and Judge Bryson required comparing both the
structure and utility to what was found in nature.125 Judge Moore and Judge
Bryson both focused on structural differences as a factor in there being
“markedly different characteristics,” but neither considered structural
differences to be the sole determination of “markedly different
characteristics.”
Upon review, the Supreme Court addressed whether a substance
isolated from a product of nature constituted patentable subject matter. The
Supreme Court held that naturally occurring DNA segments were products
of nature and not patentable subject matter simply by being isolated,
whereas cDNA was patentable subject matter because it was not naturally
occurring.126 The Supreme Court reasoned that genes contained in the
form of cDNA would be patentable subject matter because cDNA is a
synthetic creation by scientists.127 In determining that cDNA was
patentable subject matter, the Supreme Court articulated that an artificial
process of reverse transcribing mRNA in vitro was not naturally
occurring.128 The Supreme Court never stated cNDA satisfied or needed
to satisfy “markedly different characteristics” from nature to be patentable
subject matter.129 While the Supreme Court identified a synthetic product
as being non-naturally occurring, its reasoning neither discussed
“markedly different characteristics” nor gave a clear standard for
determining patentable subject matter.
D.

Guidance from the USPTO

The Supreme Court in the Chakrabarty and Myriad decisions missed
a chance to define unpatentable subject matter. The Supreme Court in
Chakrabarty130 addressed that man-made life forms were patentable
subject matter and in Myriad131 determined that cDNA as a synthetic
creation was patentable subject matter. But the Supreme Court did not
define with sufficient detail what constituted “man-made” and “synthetic.”
These ill-defined labels were subjective, simplified, and vague. The labels
were effectively an “I know when I see it”132 test and avoided the
underlying analysis of patentable subject matter.
125. Id. at 1351, 1367–78.
126. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 2113 (2013).
127. Id. at 2119 (reasoning that even though the genes contained in cDNA do occur in nature,
cDNA itself does not occur in nature).
128. Id. at 2107.
129. See Wamsley, supra note 110.
130. See Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980).
131. See Ass’n for Molecular Pathology, 133 S. Ct. at 2119.
132. Jacobellis v. Ohio, 378 U.S. 184, 197 (1964) (considering “I know it when I see it” as a
categorical exclusion to the protection of obscenity in the First Amendment).
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These cases provided significant uncertainty for lower courts and the
USPTO, which responded by initially issuing guidance in March 2014 and
June 2014 to assist USPTO examiners with determining what constituted
patentable subject matter.133 After practitioners responded with criticism,
the USPTO issued a new “Interim Guidance on Patent Subject Matter
Eligibility” in December 16, 2014 (hereinafter Interim Guidance) and
provided numerous examples applying their guidance to products of
nature.134
The Interim Guidance provides a bifurcated method for analyzing
patentable subject matter for product claims and method claims, with the
question of whether a product claim directed to natural phenomena has
markedly different characteristics from its origin in nature.135 The Interim
Guidance instructs USPTO examiners to apply their broadest reasonable
interpretation136 in applying the Supreme Court’s reasoning as follows:
1. Step 1: “Is the claim to a process, machine, manufacture, or
composition of matter?” If yes, then go to Step 2. If no, then claim
is not patentable subject matter.
2. Step 2A: “Is the claim directed to a law of nature, a natural
phenomenon, or an abstract idea (judicially recognized
exceptions)?” If no, the claim is eligible as patentable subject
matter, and the claim should be examined for patentability. If yes,
go to Step 2B.
3. Step 2B: “Does the claim recite additional elements that
amount to significantly more than the judicial exception?” If yes,
the claim is eligible for patent protection and should be patentable
subject matter. If no, then claim is not eligible as patentable
subject matter.137
The Interim Guidance reiterates under Step 1 that a claim is eligible
under 35 U.S.C § 101 as long as the claim is directed to one of the four
133. Cong Yao et al., Patent Eligibility of Nature-Based Products: Current View of the United
States Patent & Trademark Office, 11 INDUS. BIOTECH. 91, 91 (2015), https://www.fr.com/
wp-content/uploads/2014/10/230826.pdf [https://perma.cc/DH9G-WMW6].
134. U.S. PATENT & TRADEMARK OFFICE, 2014 INTERIM GUIDANCE ON PATENT SUBJECT
MATTER ELIGIBILITY 79 FR 74618-01 (2014), http://federalregister.gov/a/2014-29414
[https://perma.cc/2DRB-4PFB].
135. Roy P. Isaac et al., Analysis of USPTO’s 2014 Interim Guidance on Patent Subject Matter
Eligibility: Impact on Hightech Biotech Industries, AM. INTELL. PROP. L. ASS’N (Jan. 2015),
http://www.aipla.org/committees/committee_pages/Biotechnology/HT/Shared%20Documents/HT_
Buzz_201501.pdf [https://perma.cc/B2Z2-VKZE].
136. MPEP, supra note 65, § 2111 (stating that during patent examination, the pending claims
must be “given their broadest reasonable interpretation consistent with the specification”).
137. See Yao et al., supra note 133, at 91.
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statutory categories of process, machine, manufacture, and composition of
matter.138 Most product claims should easily satisfy the first step in the
Interim Guidance analysis.
For products claims that are directed to natural phenomena, Step 2A
considers whether the claimed subject has markedly different
characteristics from its counterpart in nature based on the product’s
structure, function, and/or properties.139 The conceptualization of what can
be “markedly different characteristics” is broader in the Interim Guidance
than in the original March 2014 and June 2014 Guidelines, which limited
“markedly different characteristics” to only structural changes and
excluded functional changes from products of nature.140 The Interim
Guidance’s Step 2A declares a nature-based product that is not directed to
a judicial exception because it is markedly different would be patentable
subject matter.141
The Interim Guidance’s statement that “even small change can result
in markedly different characteristics”142 seems to suggest a lenient
standard in covering nature-based products.143 Since USPTO patent
examiners must apply the broadest reasonable interpretation allowed by
the USPTO, then Step 2A seems to suggest a broad framework where
biotechnological discoveries aided by man and not simple repetitions from
nature could be patentable subject matter.144 The USPTO Interim
Guidance provides non-limiting examples that qualify as being “markedly
different,” including: biological or pharmacological functions, chemical
and physical properties, phenotype, including the functional and structural
characteristics of an organism, and structure and form.145
Under the Interim Guidance Step 2A, if a patent claim is indeed
directed to a judicial exception because it not “markedly different,” then
the USPTO examiner is required to analyze whether the claimed matter is

138. Ryan M. Corbett, USPTO Issues Patent Eligibility Guidelines… So Now What?, INSIDE
COUNSEL (Mar. 11, 2015), http://www.insidecounsel.com/2015/03/11/uspto-issues-patent-eligibilityguidelines-so-now [https://perma.cc/D9D3-UXM4].
139. See Isaac, supra note 135.
140. See Yao et al., supra note 133, at 91.
141. Id. at 91–93.
142. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134.
143. See generally Yao et al., supra note 133.
144. Id.
145. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134,
at 10 (further defining the markedly different examples as follows: a biological or pharmacological
function or activity could be a bacterium’s ability to infect leguminous plants or the protein-encoding
information of a nucleic acid; chemical or physical properties could be the alkalinity of a chemical
compound, or the ductility or malleability of metals; a phenotype’s functional or structural
characteristics could be the shape, size, color, and behavior of an organism; and structure and form
could be the physical presence of plasmids in a bacterial cell or the crystalline form of a chemical).
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“significantly more” than the judicial exception.146 The Interim Guidance
give numerous factors that appear to depend on the claim language and
specific facts of the technology.147 While some commentators suggest that
differential structure features would garner a technology to be patentable
subject matter, the inherent vagueness of what could be “significantly
more” is not conclusive. Examination under Step 2B is simply ill-defined.
Thus, it appears that a product of nature with a patent claim
encompassing a structure, function, or property different than that found
in nature would be considered patentable subject matter. However, the
Interim Guidance does not give a clear standard on what constitutes a
changed structure, function, or property.148 While examples are provided,
no bright-line test appears to delineate the boundaries of a structure,
function, or property. Moreover, the Interim Guidance forecloses
something other than a change in structure, function, or property can
achieve a “markedly different characteristic” than that found in nature.149
In addition, the Interim Guidance does not mention whether any
changes to a human organism would be considered markedly different in
structure, function, and/or property.150 The Interim Guidance assumes that
products of nature are biological but does not consider any limitations to
nature, such as whether human organisms are prohibited from
consideration. For example, a product of nature in human form that
undergoes a markedly different change could conceivably be patentable
subject matter under the Interim Guidance. Another avenue for patenting
a nature-based product of human form would be to fulfill the requirements
in the American Invents Act. In other words, the lack of reference to
humans in the Interim Guidance does not eliminate patentable subject
matter requirements found elsewhere. The next Section evaluates how
patentable subject matter of nature-based products must still pass the
requirements in the AIA, and Part III analyzes both the requirements of
the Interim Guidance and the AIA with the advent of 3D bioprinting.

146. Id.
147. See Isaac et al., supra note 135, at 92 (summarizing that factors supporting patentable
subject matter include improvements to another technology, improvements to functioning of a
machine, effecting a transformation or reduction of a particular article to a different state or thing,
adding a specific limitation other than what is well-understood, or adding unconventional steps; further
summarizing that factors that cut against patentable subject matter include mere inclusion of
instructions to implement an abstract idea on a computer, appending well-understood activities
previously known to the industry, appending insignificant extra-solution activity, or mere data
gathering in conjunction with a law of nature or abstract idea).
148. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134.
149. Id.
150. Id.
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America Invents Act’s Silent Amendment with Undefined Human
Organism

The Supreme Court opinions in Chakrabarty and Myriad fell short
on prescribing a bright-line test for the patent eligibility of biotechnology
inventions.151 The USPTO Interim Guidance centers on nature-based
products and does not consider how to evaluate human organisms.152 By
not considering human organisms in relation to nature-based products that
undergo markedly different changes, the Interim Guidance presupposes
that AIA’s reference to human organisms is an exception to patentable
subject matter.
Section 33 of the AIA states “notwithstanding any other provision of
law, no patent may issue on a claim directed to or encompassing a human
organism.”153 However, the words “directed to,” “encompassing,” and
“human organism” in Section 33 are undefined. While the words “directed
to” and “encompassing” are well known terms of patent practice, the
phrase “human organism” can be construed broadly.154 Because “human
organism” is undefined in the AIA, the USPTO and the courts lack the
information necessary to determine the correct scope of patents claiming
aspects of human organisms. While the AIA attempts to redefine how a
“human organism” is patentable subject matter, it will likely be left to the
courts to decide what the law means.
In effect, the AIA’s lack of definition of the phrase “human
organism” serves as a silent amendment by Congress to restrict the
patentable subject matter doctrine. The AIA serves as public law that
prohibits any form of “human organism” from being patentable subject
matter without an explicit definition. As a sub silentio reference to
patentable subject matter, the AIA serves as an implicit amendment to
what inventions can be patented under Section 101. Said another way,
“human organism” and “markedly different” are considered two separate
evaluation criterion that must both be satisfied under patentable subject
matter doctrine.

151. See supra notes 78, 117, 120 and accompanying text.
152. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134
and accompanying text.
153. Leahy–Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011) (codified as
amended in scattered sections of 35 U.S.C.).
154. This Section briefly investigates “directed to” and “encompassing” because each is
commonly used and not considered vague in patent law practice. The analysis of “directed to” and
“encompassing” is tied to its interaction with the term “human organism,” which can have varying
definitions in technology and patent law. A central claim of this Article is that the phrase “human
organism” will need to be better defined in light of the advent of 3D bioprinting, which will require
patent law to evolve as advances in 3D bioprinting technology and novel applications will create
tensions with existing patent law.
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In reviewing Section 33, the relevant question as it relates to the
scope of this Article in Part III is whether 3D bioprinting and its outputs
can be excluded as patentable subject matter.155 Such a determination
cannot be made by a rote application of Section 33’s language, but also
includes statutory construction, legislative history, and congressional
intent.
1.

Statutory Construction of “Human Organism”

While statutory interpretation as a tool can help us understand the
meaning of a statute, there are a multitude of techniques and a host of
problems that arise with any approach to interpretation. Statutory
interpretation includes strict constructionist, textualist, or purposivist
approaches.156A strict constructionist approach uses canons and rules of
interpretation to establish the meaning of the words in the statute; this
literal approach takes a statute in its ordinary literal and plain meaning.157
A textualist approach interprets words in the context apparent to a
reasonable person and in the context of the underlying purpose of the
statute. Textualists give the actual words respect, rather than sticking
religiously to interpreting them; they do not consider legislators’
psychological intentions and expectations.158 The purposivist approach
focuses on the purposes of the statute, which suggests that the legislature
is made up of “reasonable persons pursuing reasonable purposes
reasonably.”159
Each of these approaches to statutory interpretation can be used to
interpret the meaning of Section 33 of the AIA. However, because
“directed to,” “encompassing,” and “human organism,” are not defined in
155. Leahy–Smith America Invents Act § 33.
156. Richard H. Fallon, Jr., The Meaning of Legal “Meaning” and Its Implications for Theories
of Legal Interpretation, 82 U. CHI. L. REV. 1235, 1243–44, 1269 (2015) (inquiring about the definition
of “meaning” and suggesting that theories regarding the meaning of legal provisions share concerns
about communicative content; further delineating that literalists (or strict constructionists) discern
meaning solely from dictionary definitions, the rules of grammar, or the meaning of a sentence
emerging from a combination of elements, textualists embrace context-dependent meanings, and
purposivists seek to understand the product of reasonable legislators seeking to pick out reasonable
meaning).
157. See Fallon, supra note 156.
158. Richard H. Fallon, Jr., Three Symmetries Between Textualist and Purposivist Theories of
Statutory Interpretation—And The Irreducible Roles of Values and Judgment Within Both, 99
CORNELL L. REV. 685, 685–87, 707–09 (2014) (discussing that texualists emphasize a statute’s
“semantic context,” seek to understand how a reasonable person would understand statutory language
in context, and hold that judges should strive to exclude their own values from the interpretive
process); Cory R. Liu, Textualism and the Presumption of Reasonable Drafting, 38 HARV. J.L. & PUB.
POL’Y 711 (2015).
159. Victoria Nourse, Misunderstanding Congress: Statutory Interpretation, the
Supermajoritarian Difficulty, and the Separation of Powers, 99 GEO. L.J. 1119, 1147–48 (2011).
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the AIA, the interpretations will inherently yield differing results. A lack
of defined terms is particularly problematic because a broad range of
inventions treating humans could be invalidated, and contentious future
litigation depends on the interpretation of these words.
First, the phrase “directed to” under the strict constructionist
approach would yield a dictionary definition of “to go in a desired
direction; aim,” and under a textualist approach in the context of its
appearance in the AIA, would mean “to control or conduct the affairs
of.”160 Second, the phrase “encompassing” under the strict constructionist
approach would yield a dictionary definition of “including (something) as
a part.”161
Additionally, under the purposivist approach, the AIA’s terms
“directed to” and “encompassing” could be interpreted differently in
patent practice vernacular. Because reasonable patent practitioners
sometimes use the phrase “directed to” to indicate the core of a claimed
invention, then “directed to . . . a human organism” could permit patenting
of a human being per se. Similarly, because the word “encompassing” is
sometimes used by patent practitioners as an open transition defining
phrase (such as “comprising” or “including”) to define a specific patent
claim’s elements, then “encompassing a human organism” could mean
that humans could be an element of an invention. Thus, the purposivist
approach in patent practice vernacular suggests broad interpretations of
“directed to” or “encompassing” humans; this leaves open a possibility
that a judge could construe either “directed to” or “encompassing”
differently, further confusing the matter.
Third, the phrase “human organism” is the most confounding aspect
of Section 33 of the AIA, which leaves the phrase undefined. Moreover,
the entire phrase “human organism” is undefined in most dictionaries,162
although both of the words “human” and “organism” can have varying
definitions.163 Thus, the strict constructionist approach and the textualist
approach would yield differing results. However, the purposivist
approach, which centers on the purpose of the statute, could give some
guidance through an understanding of the legislative history, described
directly below.

160. Ava Caffarini, Directed To or Encompassing a Human Organism: How Section 33 of the
America Invents Act May Threaten the Future of Biotechnology, 12 J. MARSHALL REV. INTELL. PROP.
L. 768, 779 (2013).
161. MERRIAM–WEBSTER’S COLLEGIATE DICTIONARY (11th ed. 2003).
162. Id.
163. See Caffarini, supra note 160, at 781 (defining a possible definition of “human” as being
“of, pertaining to, or characteristic of humankind or people” and “organism” as being “any living
entity that contains one or more cells”).
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Legislative History of Human Organism

As a general rule of statutory construction, a statute is construed to
give effect to both the language of the statute and the intent of the
legislature, with the language carrying more weight.164 Even though the
starting point of statutory interpretation is the language itself, absent a
clearly expressed legislative intention to the contrary, at the very least
legislative history can answer the general question of why Congress is
making a particular law.
The USPTO and courts can use legislative authority for assessing
whether 3D bioprinted material is patentable subject matter because
legislative history can guide the interpretation of a statute.165 Legislative
history of the AIA supports there being varying perspectives regarding
“human organisms” as patentable subject matter. However, the legislative
history of Section 33 has been riddled with contradictions, ad-hoc
exceptions, and a lack of coherent guiding principles.166 The term “human
organism” is not defined, seemingly left open for the USPTO and for the
courts to determine.
The sponsors of the AIA had utilized a prior legislative act, known
as the “Weldon Amendment” of the Consolidated Appropriations Act, that
became codified in Section 33.167 But even the Weldon Amendment does
not contain a definition of “human organism,” and its legislative history
contains internal contradictions. The Weldon Amendment and remarks
made by Representative Lamar Smith in the legislative history of the AIA
each specify:
Nothing in this section should be construed to limit the ability of
the USPTO to issue a patent containing claims directed to or
encompassing:
1. any chemical compound or composition, whether obtained from
animals or human beings or produced synthetically, and whether
identical to or distinct from a chemical structure as found in an
animal or human being, including but not limited to nucleic acids,
polypeptides, proteins, antibodies, and hormones;
2. cells, tissue, organs or other bodily components produced
through human intervention, whether obtained from animals,
164. Enzo Biochem, Inc. v. Gen-Probe Inc., 323 F.3d 956, 971 (Fed. Cir. 2002).
165. Deluxe Corp. v. United States, 885 F.2d 848, 850 (Fed. Cir. 1989) (“[W]here the text itself
does not clearly exclude alternate interpretations, we look first to the legislative history for
illumination of the intent of Congress.”).
166. Yaniv Heled, On Patenting Human Organisms or How the Abortion Wars Feed into the
Ownership Fallacy, 36 CARDOZO L. REV. 241, 244 (2014).
167. Id. at 256.
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human beings, or other sources; including but not limited to stem
cells, stem cells derived tissues, stem cell lines, and viable
synthetic organs;
3. methods for creating, modifying, or treating human organisms,
including but not limited to methods for creating embryos through
in vitro fertilization, methods of somatic cell nuclear transfer,
medical or genetic therapies, methods for enhancing fertility, and
methods for implanting embryos;
4. a nonhuman organism incorporating one or more genes taken
from a human organism, including but not limited to a transgenic
plant or animal, or animal models used for scientific research.168
Even though such legislative history provides a negative limitation
on what may be permitted as patentable subject matter, it does not clarify
what may be the boundary of patentable subject matter. Because the
legislative history does not delve into what may not be patentable subject
matter, inventors do not have guidance when technologies enable
inventions that are not specified in a category. The negative limitations
specify the phrases “produced synthetically,” “produced through human
intervention,” “treating human organisms,” and “nonhuman organism,”
but do not describe the boundary limits of each phrase. Each of these
phrases can extend beyond the scientific understanding of the current
definition of the phrase with the advent of a new technology. For example,
the advent of 3D bioprinting redefines what some of these phrases mean
or provides new examples that were not envisioned previously. This is
investigated further in Part III.
This Part suggested that the AIA contains no explanation or
definition of what “human organism” means, nor how to apply the law.
Without clarity on what “human organism” means in patent law, there is a
lack of guidance for the USPTO and the courts. While the AIA attempts
to redefine how a human organism is patentable subject matter, it will
likely be left to the courts to decide what the law means. Part III evaluates
“human organism” in the context of 3D bioprinting and suggests that the
advent of 3D bioprinting complicates what a human organism may be and
introduces new capabilities to transform some aspect of a human
organism. The legislative history of the AIA has not considered emerging
technologies such as 3D bioprinting, and its unclear definitions are further
obfuscated with new applications that are just being imagined by
inventors.
168. 157 CONG. REC. E1182–85 (daily ed. June 23, 2011) (statement of Representative Lamar
Smith) (emphasis added).
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APPLICATION OF PATENTABLE SUBJECT MATTER REQUIREMENT
TO 3D BIOPRINTING

The ability to produce living human cells with 3D bioprinting
pressures the patent regime. The line between living and nonliving is
effectively eroding with 3D bioprinting. This Part confronts this situation
directly by investigating 3D bioprinting applications that raise uncertainty
with patentable subject matter in light of: 1) the unclear “markedly
different characteristics” standard set by courts and the USPTO,169 and 2)
the unclear reference to “human organism” in the AIA and its legislative
history.170
This Part also considers the interplay between the human organism
exception and the markedly different characteristics standard in the realm
of 3D bioprinting. It investigates 3D bioprinting technology’s ability to
challenge patentable subject matter doctrine in ways not imagined by other
technologies. First, this Part considers the case of a human organism
element input into a 3D bioprinting operation that creates a modified
output lacking the human organism element. Second, and perhaps more
importantly, this Part considers 3D bioprinting applications where a 3D
bioprinted material contains markedly different characteristics than that
found in nature, but may still be considered human and therefore not
qualify as patentable subject matter under the AIA.
3D bioprinting, like biotechnology in general, can modify products
of nature. Unlike other biotechnologies, however, 3D bioprinting
processes can co-mingle living and nonliving worlds, either during the 3D
bioprinting process or later in integrating 3D bioprinted materials into the
human body. Even if 3D bioprinted tissues and organs are not viewed as
products of nature, they may still be considered human. This Part
investigates the continuum of what may be considered human in light of
3D bioprinting. It analyzes patentable subject matter by examining: What
does a human organism mean under patent law for 3D bioprinting? Where
does the boundary of a human organism stop and the boundary of the
nonhuman organism world begin? What is considered a human organism
where products of nature are mixed with artificial, nonhuman organism
elements?

169. See supra notes 104–147 and accompanying text (explaining the historical and current
status of the standard for determining patentable subject matter in the context of biotechnological
inventions).
170. See supra notes 153–168 and accompanying text (explaining the statutory and legislative
history of the AIA in the context of human organism concerning patentable subject matter).
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3D Bioprinting Applications Magnify the Human Organism
Ambiguity

3D bioprinting illustrates the problems created by leaving the phrase
“human organism” open to judicial construction. The technological
capabilities of 3D bioprinting can be assessed to identify how, if at all,
“human organisms” applies or further magnifies the deficiencies,
ambiguities, and inconsistencies within the legislative history of the
Weldon Amendment and Section 33 of the AIA.
First, can 3D bioprinting be considered to fall within produced
synthetically? Presumably, this part of the Weldon Amendment171 means
“by chemical synthesis” because the accompanying text specifies a
chemical compound or composition. In the realm of biological
applications, synthesis could either be by chemical synthesis or synthetic
biology, which refers to the design and fabrication of biological
components that do not exist in the natural world, or the redesign of
existing biological systems.172 Thus far, synthetic biology has imported
engineering principles into traditional biological sciences and attempted to
remake living systems at the molecular level.173 While 3D bioprinting
technology does enable synthesizing biological components, it does not
build living material at the molecular level; instead it builds living material
at the cellular level, resulting in aggregation of tissues and organs.174 On
the other hand, synthetic biology’s definitions and applications are based
on genetic engineering, genetic programming, and biological
engineering.175 Because the first statement of the Weldon Amendment176
does not account for cellular production, the drafters did not consider 3D
bioprinting technology in exempting synthetic production of anything
human. However, other statements in the Weldon Amendment177 could
encompass 3D bioprinting, even though it is not stated.
Second, is 3D bioprinting considered made by human intervention?
Generally speaking, any type of 3D printer would be considered made by
human intervention and operated by human intervention through a click of
a button or by computer control; therefore, 3D bioprinting, as a subset of
3D printing, would be considered a human intervention operation.

171. See supra notes 166–168 and accompanying text.
172. What Is Synthetic Biology?, SYNTHETIC BIOLOGY, http://syntheticbiology.org/FAQ.html
[https://perma.cc/434U-GRCU].
173. See Torrance, supra note 102.
174. Christian Mandrycky et al., 3D Bioprinting for Engineering Complex Tissues, 34 BIOTECH.
ADVANCES 422, 422–34 (2016).
175. See Torrance, supra note 102.
176. See supra notes 166–168 and accompanying text.
177. Id.
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However, other facets of the 3D bioprinting systems, such as Bio-CAD178
files, can arguably function without human intervention once created. This
is problematic because Bio-CAD files are digital blueprint instructions to
print objects and are essentially representative of the objects themselves.179
Patentees can attempt to capture the eventual 3D bioprinted object in a
patent claim encompassing the digital instructions of the 3D bioprinted
object.180 Some Bio-CAD files may be created in an automated fashion by
computer control that transposes medical images into a virtual image on a
computer.181 Because some Bio-CAD may not require human intervention,
patent claims that capture the files as representative blueprint instructions
of the biological product or biomaterial to be 3D bioprinted may not be
patentable subject matter for effectively being a human organism under
this aspect of the Weldon Amendment.182
Third, can 3D bioprinting be considered a method for treating human
organisms? While 3D bioprinting can provide healthcare benefits to treat
human organisms,183 not all 3D bioprinted materials have a medicinal
effect on patients. 3D bioprinted devices such as customized replacement
body parts, tailor-fabricated organs, and 3D bioprinting enabled in situ
skin repair would provide treatment to humans, but other 3D bioprinting
applications, such as emerging wearable microbiomes, typically are not
178. See Sun et al., supra note 32.
179. See Osborn, supra note 19, at 1328 (discussing that as a technological matter, there is little
difference between digital files and tangible objects with 3D printing because the digital file and
physical printed item can be viewed as interchangeable).
180. See Brean, supra note 2.
181. See generally Biomedical Modeling Inc.: Biocad, DASSAULT SYSTEMS: SOLIDWORKS,
http://www.solidworks.com/sw/products/details.htm?productID=529
[https://perma.cc/TJG2QVKY].
182. See supra notes 166–168 and accompanying text.
183. It should be noted that in U.S. patent law, 35 U.S.C. § 287(c) creates a liability exception
for medical practitioners infringing medical treatment method patents while performing a medical
activity with the goal of treating a human being. See 35 U.S.C. § 287(c) (2011). This means that a
medical practitioner who infringes a medical treatment method patent is immune from liability to the
patentee for any infringement of the patent during the performance of the medical treatment activity.
Essentially, 35 U.S.C. § 287(c) deprives a patentee of its infringement remedies (such as a civil trial,
injunction, damages, and attorney’s fees) where a medical practitioner or a related healthcare entity
(such as a hospital, health maintenance organization, or nursing home) performs a patented medical
activity.
Therefore, the doctors and healthcare entities who utilize 3D bioprinting inventions for treatment
would be immunized from liability for infringement of the 3D bioprinting medical treatment method
patents. However, what may be considered “treatment” with the use of 3D bioprinting inventions is
unclear. Since other statutory categories of machine, manufacture, or composition of matter may be
patented, the medical activity utilizing those types of inventions would not be immunized from patent
infringement claims. Thus, courts will need to clarify what kinds of 3D bioprinting inventions and
their uses for medical treatment would constitute “medical activity” under the statute. Presumably,
insofar as 3D bioprinting digital design files and 3D bioprinted materials are not medical or surgical
procedures, then 35 U.S.C. § 287(c) should not cover the patents drawn to such inventions.
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being considered treatment and instead are being considered for fashion or
spacesuit design.184 The list of permitted treatment categories in the
Weldon Amendment185 is limited and ignores cases where human
organisms are involved, but not necessarily for treatment.
Fourth, the Weldon Amendment186 ignores technologies lacking
utilization of a nonhuman organism incorporating one or more genes. The
Weldon Amendment was written with the intention of limiting stem cell
usage,187 but was not aimed to suppress genetic engineering development.
It focuses on permitting genetic engineering from animal or plant sources
and ignores 3D bioprinting, which does not incorporate genetics and
instead functions at a cellular level. Moreover, by defining “nonhuman”
in attempting to define what may or may not be human, the Weldon
Amendment and the legislative history of the AIA conflates what
legislators consider a definition of human.
In sum, the Weldon Amendment188 and legislative history of the AIA
do not effectively address what is human and what is nonhuman. The
question of what may or may not be considered a human for the purposes
of Section 33’s legislative history is ambiguous. This analysis shows that
the legislative history of the AIA did not consider the advent of 3D
bioprinting. Thus, the lack of clear legislative guidance on patentability
further demonstrates that the law must adapt to the challenges offered by
emerging technologies such as 3D bioprinting. Alternatively, and as
supported by some commentators, without interpreting legislative history,
the meaning of Section 33 will either need to be found elsewhere or be
based on guidance by federal courts.189 This is problematic in U.S. patent
law, which requires clarity in administering patent examination by the
USPTO. Ultimately, unless there is further legislative action, inventors
will need to wait until federal courts define how some portion of “human
organism” is captured in a patent claim.
B.

Bio-CAD Files May or May Not Be Patentable Subject Matter

As mentioned, Bio-CAD190 files are a digital representation of a
human organism or a body part of a human organism. Bio-CAD191 files
184. See supra notes 38–57 and accompanying text.
185. See supra note 168 and accompanying text.
186. See supra notes 166–168 and accompanying text.
187. See Heled, supra note 166.
188. See supra notes 166–168 and accompanying text.
189. Andrew W. Torrance, The Unpatentable Human Being, 43 HASTINGS CTR. REP. 10 (2013).
190. See Sun et al., supra note 32.
191. Biomedical Modeling Inc.: BioCad, supra note 181 (displaying medical imaging data in the
form of CT or MRI scans that are utilized to create models of human anatomy for eventual 3D
bioprinting); BioCAD, BIOMEDICAL MODELING, INC., http://www.biomodel.com/biocad.html
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cover the information content of a medical image transposed into a virtual
object on a computer. Just like 3D printing CAD files contain digital
models of non-natural objects, Bio-CAD files contain digital models192 of
a natural or biological object.193 Bio-CAD files, like any 3D printing CAD
file, contain digital blueprint instructions for an object in the form of a
digital 3D model.194 Medical images of a biological tissue or organ in an
MRI or CT scan can be transformed into CAD files as 3D bioprinting
ready files.195

[https://perma.cc/ST96-UFNP] (2017) (showcasing that CT and MRI data can be reconstructed into
accurate anatomical representations, which is the information content instruction to a 3D bioprinter).
192. This Article does not investigate whether Bio-CAD files could be copyrighted to protect
some digital aspects of 3D bioprinting technologies. For a discussion on how 3D printing (or 3D
bioprinting, which is a subset of 3D printing) fits within U.S. copyright law, see Peter S. Menell &
Ryan G. Vacca, 3D Printing and U.S. Copyright Law (UC Berkeley Public Law Research Paper No.
2859737), https://ssrn.com/abstract=2859737 [https://perma.cc/3JBR-W57E] (discussing that CAD
files or physical objects generally would qualify for copyright protection, but there could be three main
reasons for copyright law’s exclusion of protection of CAD files: 1) The functional aspects of works
of authorship erects a significant barrier to copyrightability of CAD files and three-dimensional
objects; 2) The difficulty in separating form from function poses a problem, since many 3D printing
designs combine aesthetic and functional features; and 3) Owners of the CAD file would face legal
and practical challenges enforcing its copyright, particularly in how to target copyright infringement
among Internet Service Providers and software application vendors). For a discussion on doctrinal
copyright law issues with 3D printing technology that are related to originality, useful articles, and the
functionality doctrine, see Lucas S. Osborn, Of PhDs, Pirates, and the Public: Three-Dimensional
Printing Technology and the Arts, 1 TEX. A&M L. REV. 811 (2014).
193. Given that the U.S. Copyright Office has rejected copyright registration for genetically
engineered DNA sequences, a proposed copyright on Bio-CAD files may not achieve registration with
the U.S. Copyright Office. In addition to the challenges for copyrightability identified in supra note
192 and infra note 198, there are biological-specific challenges to copyright protection. See
Christopher M. Holman et al., Are Engineered Sequences Copyrightable?: The U.S. Copyright Office
Addresses a Matter of First Impression, 35 BIOTECH. L. REP. 103, 104–08 (2016) (discussing the
analogy between engineered genetic code and computer code, and suggesting that Congress should
amend the Copyright Act to explicitly identify genetic code as a category of copyrightable subject
matter; further suggesting genetic code would unlikely be copyrightable in the near term, especially
in light of the U.S. Copyright Office’s rejection of a synthetic DNA sequence by DNA 2.0, a leading
gene synthesis and design company).
194. Sklyer R. Peacock, Why Manufacturing Matters: 3D Printing, Computer-Aided Designs,
and the Rise of End-User Patent Infringement, 55 WM & MARY L. REV. 1933, 1937 (2014).
195. See Michael P. Chae et al., Emerging Applications of Bedside 3D Printing in Plastic
Surgery, FRONTIERS IN SURGERY, June 16, 2015, at 1, 4–5 (providing that 3D modeling software can
translate a CT/MRI scan into a CAD file, and 3D slicing software can divide the CAD files into thin
data sets suitable for 3D printing); Michael W. Itagaki, Using 3D Printed Models for Planning and
Guidance During Endovascular Intervention: A Technical Advance, 21 DIAGNOSTIC AND
INTERVENTIONAL RADIOLOGY 338 (2015) (demonstrating the use of data from a patient’s CT scan
and free open-source software, to develop a CAD file of a patient-specific, hollow, and small-caliber
vascular model treatment of a difficult and unconventional aneurysm while preserving splenic
function); Wuyang Shui et al., The Production of Digital and Printed Resources from Multiple
Modalities Using Visualization and Three-Dimensional Printing Techniques, 12 INT’L J. OF
COMPUTER ASSISTED RADIOLOGY AND SURGERY 13 (2016) (validating that neuroimaging
technologies such as CT, CTA, MRI, and TOF-MRA of medical images can be transformed into CAD
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However, until a Bio-CAD has been modified by human or computer
interaction, the Bio-CAD file is a static and visual representation of a
biological object that is a click of the mouse away from being 3D
bioprinted after it is created. Thus, an unmodified Bio-CAD file of a
human organism is information content of a human organism in a digital,
pixel representation that can be 3D bioprinted with de minimis effort. The
line between digital and tangible in 3D printing, as well as in 3D
bioprinting, is undefined, and CAD files, such as Bio-CAD files, can be
considered as representing the object itself.196 Would a Bio-CAD file be
tantamount to a human organism itself under a vague, markedly different
characteristics standard and undefined human organism exception?
Since a CAD file, such as a Bio-CAD file, is simply information in
the form of a data package that describes the properties of the object,197
then it could arguably represent the human organism or a body part of the
human organism itself in digital form.198 This feature could disqualify a

files, which can undergo volume rendering and medical image reconstruction, before being 3D
printed).
196. See Osborn, supra note 19, at 1331 (specifying that a CAD file can be created from scratch
using a computer program or by scanning an object, and under either scenario, the CAD file is a digital
representation of the physical object that is printed).
197. See Peacock, supra note 194, at 1948–51 (describing that the information in a CAD file is
best understood as a collection of facts and may either be protected by copyright law or by patent law,
depending on how the schematics in CAD files are defined).
198. This Article focuses on patent law, particularly on patentable subject matter. There may or
may not be copyright protection for Bio-CAD files, but the law is unclear in that aspect and that topic
is beyond the scope of this Article. However, because digital technology in the form of Bio-CAD files
is discussed in this Article, for completeness, a brief discussion of the applicability of U.S. copyright
law is provided here.
It should be noted that U.S. copyright law considers computer programs to be literary works
under the Copyright Act in 17 U.S.C. § 10. U.S. copyright law holds that a copyright attaches only to
an original work, which is created when it is fixed in a tangible medium of expression for the first
time. Thus, source code to the extent that it reflects the original expression is copyrightable, whereas
object code (especially when stored on ROM) is regarded as being part of a machine and is not
protectable by copyright. Source code refers to the code actually written by the author in a particular
programming language, whereas object code is the code generally translated from the original
programming language and compiled by a computer into a machine-readable representation (defined
as a string of zeros and ones that are interpretable by a computer). However, object code has been held
to be copyrightable by the Ninth Circuit when the computer program, when written, embodies
expression (in other words, a computer program that is written in object code and reflective of the
original expression is copyrightable subject matter).
The case that is historically deemed to have decided the “copyrightability of computer programs”
is the famed Apple Computer, Inc. v. Franklin Computer Corporation case. Apple Computer, Inc. v.
Franklin Computer Corp., 714 F.2d 1240 (3rd Cir. 1983). In the case, Franklin Computer was
producing a clone of the Apple II computer and had copied both the Apple ROM and a number of
computer programs from Apple Computer. Franklin Computer argued that Apple’s operating system
programs were not protectable under copyright law. The Court held that Franklin Computer’s
contention that operating system programs are per se not copyrightable was not persuasive. The
relevance is that a computer program’s object code, which is more machine-oriented than the original
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Bio-CAD file from being considered patentable subject matter, even
before any disqualification for abstractness under 35 U.S.C. § 101.199
While some commentators may argue that a Bio-CAD file would not be
considered an entire human organism, a scan of any body part of a human
may arguably be construed as being a human organism under the
deficiencies of the Weldon Amendment of the AIA.200 Thus, unlike CAD
files, which some commentators have argued cannot be patentable because
they are software instructions,201 Bio-CAD files may not be patentable
subject matter under an ill-defined human organism exception.
The AIA could prohibit a Bio-CAD file from being patentable
subject matter as a human organism. Moreover, assuming arguendo that
somehow a Bio-CAD file did qualify under the AIA as patentable subject
matter, the USPTO Interim Guidance202 would prohibit the Bio-CAD file
from being patentable subject matter for not exhibiting markedly different
characteristics from a product of nature. Because the USPTO Guidance is
based on Myriad, which held that DNA was the physical embodiment of
information and of nature and, therefore, an unpatentable product of
nature,203 then a Bio-CAD file as information content could similarly not
be patentable subject matter.
A closer look at the Interim Guidance reveals the supporting
reasoning. Under Step 1 of the Interim Guidance, a Bio-CAD file could
conceivably be claimed as a tangible object as a component of a

source code version, should be copyrightable for software to be meaningfully protected (when outside
of patents).
In sum, the copyrightability of Bio-CAD files is unsettled. While the U.S. Copyright Office would
allow for copyright registration for the source code of a Bio-CAD file for an applicant who would be
willing to deposit the source code, the object code aspect of a Bio-CAD file would be unclear (unless
it embodies the original expression). An applicant would have to state in writing to the U.S. Copyright
Office that the work deposited as object code contained copyrightable authorship. It is well understood
that reproductions of on-screen text, buttons, and commands, such as those being shown on a computer
that displayed a Bio-CAD file, would not be appropriate as a substitute for a deposit for a source code
deposit. However, whether or not the computer language encompassing a Bio-CAD file as written in
some sort of scripted language would be equivalent to source code is unsettled and unclear, and could
be the foundation of a separate Article.
199. 35 U.S.C. § 101 (2012).
200. See Torrance, supra note 102.
201. See Brean, supra note 2, at 841 (suggesting that there is a gap in patent law that does not
account for patenting per se digital printable products because CAD files are similar to software and
might be compared to a blueprinting or anything containing design information, such as a schematic,
template, or prototype).
202. See supra notes 133–147 and accompanying text.
203. See CATO SUPREME COURT REVIEW: 2012–2013 279, 280 (Ilya Shapiro ed., 2013)
(emphasizing the “information encoded in the DNA molecule” and discussing that in Myriad the
“Court agreed . . . that DNA is primarily an information-carrying molecule” and “isolated DNA is not
patent-eligible subject matter”); see also Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133
S. Ct. 2107 (2013).
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computer.204 The more pressing issue is the markedly different
characteristics analysis. Under Step 2A of the USPTO’s new markedly
different characteristics standard,205 Bio-CAD files would not possess
markedly different characteristics from the object from which it is derived
because it has identical structure, function, or properties to the biological
object to be 3D bioprinted, but only in information content form.
Regardless of whether the Bio-CAD file was created with a 3D modeling
program or through the use of a 3D scanner, it would simply be a digital
representation or device profile206 with information concerning the color
and spatial aspects of the natural object. There would not be any difference
in structure, function, and/or properties to justify a Bio-CAD file being
markedly different from the natural object it represents. Even though other
commentators have suggested that existing law will close the gap between
the digital and tangible worlds and define patentable objects,207 Bio-CAD
would arguably not have markedly different characteristics from the object
found in nature.
Even under the subsequent Step 2B of the Interim Guidance, a BioCAD file would likely not be patentable subject matter under the
“significantly more inquiry.”208 A Bio-CAD file would likely not fit any
of the factors provided for in this step of the Interim Guidance. For
example, a Bio-CAD file would not be an improvement to another
technology, to the functioning of a machine, to effecting a transformation
or reduction of a particular article, or to adding a specific limitation other
than to what was understood. Each of these factors would cut against
patent eligibility for a static Bio-CAD file that is simply a digital
representation of a natural object.
Unlike static, unmodified Bio-CAD files that are based on MRI or
CT scans, or are created in 3D modeling programs, other Bio-CAD files

204. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134,
at 7.
205. See id. at 18.
206. While the Court in Digitech held that “data in its ethereal, non-physical form is simply
information that does not fall under any of the categories of eligible subject matter under section 101,”
when the technology at issue was “a device profile for describing properties of a device in a digital
image reproduction system,” the fundamental issue is not whether claims are abstract ideas, but instead
whether the invention is even patentable subject matter as a digital representation of a natural object.
Digitech Image Techs., LLC v. Electronics for Imaging, Inc., 758 F.3d 1344, 1349–50 (Fed. Cir.
2014).
207. See Osborn, supra note 19, at 1356 (suggesting that from an infringement standpoint, the
interest in CAD files is not the files themselves but instead the object ultimately produced. Therefore,
the reduced gap between digital and physical worlds considers CAD files to be the object itself, and
the mere creation of the CAD file would constitute infringement by making or 3D printing the object.).
208. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134,
at 18.

2017]

3D Bioprinting

41

could be modified in silico.209 Bio-CAD files, which represent an element
of a human organism in digital medical images, can also be exchanged in
a marketplace that allows others to modify the models before 3D
bioprinting.210 Bio-CAD files can also serve as preexisting modules that
can be bought and downloaded before being transmitted to a 3D bioprinter
to create a new aspect of an organism.211
Thus, Bio-CAD files not only converge digital and physical worlds,
as with CAD files, they also converge living and nonliving worlds in a
virtual environment. The convergence of living, nonliving, digital, and
physical worlds with Bio-CAD files challenges patentable subject matter
doctrine. Because of the convergence of so many technological domains,
and the potentially added complexities with post-processing and
integration,212 3D bioprinting is more highly scrutinized than 3D
printing,213 and a more in-depth assessment of patentable subject matter
would require identifying whether Bio-CAD has been modified or remains
unmodified.
Because a Bio-CAD file can be modified by changing numerical
parameters, calculating resulting geometries, and storing the models in
repositories before post-processing 3D bioprinting steps,214 living and
nonliving parameters can be altered digitally. The ability to modify in
silico alters the analysis of patentable subject matter with unmodified BioCAD files. For instance, a human organism element scanned into a BioCAD file could be modified in silico to remove or mask the human
organism element, which may not be detected as containing any human
organism element upon completion of the 3D bioprinting process. The
removal of the human organism characteristic in silico could render the
Bio-CAD file no longer a human organism, no longer falling under the
AIA exception against human organisms. Additionally, the end result 3D
bioprinted material would not fall under the AIA exception against human
organisms.

209. See Biomedical Modeling Inc.: BioCad, supra note 181.
210. See EMBODI3D, http://www.embodi3d.com/ [https://perma.cc/S46N-HD93] (offering a
website for users to share digital designs of anatomic structures).
211. Digitizing Life: The New Frontier, ATLANTIC COUNCIL (Dec. 6, 2013),
http://www.atlanticcouncil.org/blogs/futuresource/digitizing-life-the-new-frontier
[https://perma.cc/47KK-9KEK].
212. See supra notes 36–37 and accompanying text.
213. See Tran, supra note 6.
214. Mary-Ann Russon, MIT Simplifies 3D Printing By Making It Easier to Modify 3D Models,
INT’L BUS. TIMES (Sept. 7, 2015), http://www.ibtimes.co.uk/mit-simplifies-3d-printing-by-making-iteasier-modify-3d-models-1518781 [https://perma.cc/G67F-3T3J] (discussing a new, web-based
software that makes it simpler for users to make modifications to 3D models in CAD files, such as 3D
bioprinting CAD files, to print out quicker).

42

Seattle University Law Review

[Vol. 41:1

In addition, under Step 2A of the USPTO’s new “markedly different
characteristics” standard,215 a modified Bio-CAD file would likely be
found to be patentable subject matter. Because a modified Bio-CAD file
has new structure, function, and/or properties, it would be considered
patentable subject matter. A modified Bio-CAD file would have different
structure, function, and/or properties than the natural product from which
it is based and, therefore, the end result printed object would also have
different structure, function, or properties than the natural object because
the modified Bio-CAD file is the equivalent of the printed object.
Thus, the Interim Guidance with the “markedly different
characteristics” standard could produce different determinations of
patentable subject matter for a Bio-CAD file based on whether it is
modified or not. The development and growth of commercial exchanges
to share Bio-CAD files makes it a challenge to track which file is modified
and which is unaltered. For this reason, this Article proposes that the
USPTO adopt a modified standard to supplement patent law’s “markedly
different characteristics” examination of nature-based products in Part IV.
C.

Processed 3D Bioprinted Materials Should be Patentable
Subject Matter

At first glance, it can appear that 3D bioprinted living tissues
(whether for organ transplants, in vivo skin repair, or wearable
microbiomes) are nothing more than an assembly of cells organized in a
3D structure. However, 3D bioprinted tissues are manufactured by natural
growth through intrinsic self-assembly principles found in nature.216 In
such cases, where nature is emulated inside of a 3D bioprinter, the
resulting product would arguably not have markedly different
characteristics because nature is directing the creation. However, human
ingenuity is arguably the cause for the precision, automation, and
deposition of the bioink particles inside of a 3D bioprinter that produce 3D
bioprinted materials.
In other cases, the assembly of 3D bioprinting cells would be
combined with artificial materials, such that a mixed living and nonliving
3D bioprinted material would be achieved. The result is an easy case of
markedly different characteristics because the infusion of artificial
materials would structurally and visibly be considered markedly different.
215. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134,
at 18.
216. Karoly Jakab et al., Tissue Engineering by Self-Assembly and Bio-Printing of Living Cells,
BIOFABRICATION, June 2010, at 1, 9, 10 (discussing that 3D bioprinting exploits intrinsic selforganizing principles of cells and tissues, natural vessel forming processes, and morphogenetic
principles such as cell sorting and tissue fusion via automation of the deposition step that enables the
building of 3D custom-shaped tissues and organs without the use of any scaffold).
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As a conceptual example, artificial materials, such as Kevlar™, could be
introduced into a product of natural materials to be 3D bioprinted for in
vivo skin repair.
A more difficult case is 3D bioprinted materials lacking any addition
of artificial materials. Under the Interim Guidance, a manufacture of 3D
bioprinted materials would be markedly different than the materials
inputted in the 3D bioprinter, which would produce a material with a new
form, structure, function, and/or property. The current state of 3D
bioprinting—printing a scaffold, applying cells to the scaffold, and
growing the culture of cells217—provides a new form, quality, and
properties to the cells. The resulting 3D bioprinted cells claimed as a
manufacture would be markedly different218 from the natural state of the
material that is introduced into a 3D bioprinter as an input. Moreover, the
composition of matter of the resulting 3D bioprinted cells when fused
would have a new quality, whether caused by scaffold-based printing or
scaffold-free printing,219 through aggregation and perfusion from
printing.220 Thus, 3D bioprinting materials inventions would possess
physical characteristics that would qualify as patentable subject matter
because such living organisms are no longer products of nature.
Inventors can avoid the patentable subject matter challenges with
producing exact replicas by slightly modifying the 3D bioprinted object
from what appears in nature. Any change in structure, function, or
properties produced by the 3D bioprinting process specified in the patent
specification221 would deem the material patentable subject matter. Thus,
the markedly different standard does not distinguish well between slightly
modified and wholly modified 3D bioprinted materials. A clearer standard
would prevent inventors from wasting time in attempting to slightly
modify a prospective 3D bioprinting material to attempt to muster passing
an unclear USPTO examination standard. Instead, an inventor’s time
could be better spent innovating, rather than attempting to engineer
methods of slightly, but not fully, modifying products of nature through
3D bioprinting processes.
217. LIJIE GRACE ZHANG ET AL., 3D BIOPRINTING AND NANOTECHNOLOGY IN TISSUE
ENGINEERING AND REGENERATIVE MEDICINE 358 (1st ed. 2015).
218. 3D bioprinted living tissues and organs are significantly different from their human
counterparts because there are structural differences between a 3D bioprinted organ and the parent
organ brought about by laser-based writing, ink-jet based delivery, or extrusion-based deposition of
cells. Thus, the physical 3D bioprinting process itself created new form, qualities, and properties of
cells, and would be considered a manufacture.
219. See Bakhsinejad, supra note 25 (explaining bio-printing methods).
220. Ibrahim Ozbolat & Yin Yu, Bioprinting Toward Organ Fabrication: Challenges and Future
Trends, 60 IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING 691, 696 (2013).
221. Phillips v. AWH Corp., 415 F.3d 1303, 1315 (Fed. Cir. 2005) (emphasizing the importance
of the role of the patent specification as a source of meaning of patent claim terms).
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Post-Processing and Integration of 3D Bioprinted Materials is
Unsettled

In certain situations, 3D bioprinted materials may contain markedly
different characteristics than that found in nature, but may still be
considered human and not qualify as patentable subject matter under the
AIA. The post-processing of 3D bioprinted materials can infuse living,
human elements that can render what was a markedly different material
from that found in nature with a mix of living and nonliving elements. The
mixture of living and nonliving characteristics introduced by 3D
bioprinting would further challenge patentable subject matter doctrine.
The introduction of artificial materials during the final maturation process
of a 3D bioprinted material would render the product a mixed living and
nonliving material. For example, a 3D bioprinted kidney or heart could
have vascularization enabled through artificial materials.
Where 3D bioprinting challenges patentable subject matter doctrine
under the markedly different characteristics examination is the prospect of
the technological advancement to the point where 3D bioprinted tissues
and organs are indistinguishable from natural tissues and organs. When
3D bioprinted tissues and organs are identical in form and function to
natural tissues and organs, then they would be considered naturally
occurring. This reasoning has some basis in the current state of the art
because 3D bioprinted organs are not yet populated with nerves and blood
vessels in an exact replica fashion.
The state of the art of 3D bioprinted organ lacks nerves and
vasculature, which are necessary for the viability and function of the
organ.222 Developments in 3D bioprinting are advancing to the point where
nerves and blood vessels could be present. This exact replica dilemma in
3D printing is not far away. Would such a 3D bioprinted material be
considered a human organism? Where would the world of nonliving stop
and where would the world of a human organism start in this 3D
bioprinting world? Would a 3D bioprinted material with markedly
different characteristics than those found in nature be considered a human
organism under the AIA?
These perplexing questions are further complicated when 3D
bioprinted materials are integrated in a human organism. For instance,
should 3D bioprinted wearable microbiomes that nourish the skin and
repair damaged tissues be considered patentable subject matter?223 In such
a case, an argument could be made that a wearable microbiome would be
222. Ozbolat, supra note 220, at 696 (specifying that the most critical challenge for 3D
bioprinting is the integration of vascular networks, which allow 3D bioprinted organs to receive
enough nutrients and enable gas exchange and waste removal).
223. See supra notes 53–57 and accompanying text.
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considered a 3D bioprinted material integrated into a human body and
therefore, as a method of medical treatment, would be exempt from being
patentable subject matter.224
However, the integration of a 3D bioprinted material into a human
organism could be performed during the process of 3D bioprinting itself.
This could complicate patentable subject matter doctrine because the line
between treatment and 3D bioprinting would be blurred. The integration
of a 3D bioprinting material into a human being, even if the material
retains its markedly different characteristics, can introduce a nonliving
element into a human organism during the 3D bioprinting process. For
example, 3D bioprinting can enable in situ and in vivo225 deposition
operations to treat skin damage and enable wound healing.
3D bioprinting inkjet technology can easily be transported from
patient to patient to rapidly print skin constructs of any cell type or
biomaterial to treat burn victims in situ or provide artificial skin
substitutes.226 Also, 3D bioprinting proof-of-concept development has
shown the use of robotic arms with 3D bioprinting units that enter the body
to automatically reconstruct new tissues and organs under the control of
surgeons, utilizing in vivo bioreactors to facilitate the maturation of 3D
bioprinted constructs.227 While in vivo 3D bioprinting combined with
robot-assisted surgery is largely conceptual, it presents a pending
patentable subject matter challenge.
The joining of an entire organ during 3D bioprinting might be
considered too human and could be conceptually equivalent to a human
organism, therefore disqualifying it from being patentable subject matter
under the AIA. Taken to the extreme, the question arises—what if an entire
human organism could be 3D bioprinted? As it stands, what can be
considered a human organism under the AIA is unclear with respect to the
continuum from living, to mixed living and nonliving, and to nonliving in
3D bioprinting.

224. 35 U.S.C. § 287(c) (2011); Fariba Sirjani & Dariush Keyhani, 35 U.S.C. § 287(c): Language
Slightly Beyond Intent, 3 BUFF. INTELL. PROP. L.J. 13, 14–16, 35–37 (2005).
225. See supra note 38 and accompanying text.
226. Kyle W. Binder, In Situ Bioprinting of the Skin (May 2011) (unpublished Ph.D. dissertation,
Wake
Forest
University
Graduate
School
of
Arts
and
Sciences),
https://wakespace.lib.wfu.edu/bitstream/handle/10339/33425/Binder_wfu_0248D_10078.pdf?sequen
ce=1 [https://perma.cc/X6S3-9KLA] (demonstrating in a nude mouse wound model that in situ 3D
bioprinting is a viable technique for repair of full-thickness skin wounds, enabling virtually any cell
type, macromolecule, or biomaterial to be directly 3D bioprinted onto a wound).
227. Manyi Wang et al., The Trend Towards In Vivo Bioprinting, 1 INT’L J. BIOPRINTING 15,
16–22 (2015) (demonstrating pilot studies of in vivo 3D bioprinting of de novo tissues and organs that
are directly fabricated and positioned at a damaged site in a living body).
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U.S. PATENT LAW SHOULD EVOLVE ITS PATENTABLE SUBJECT
MATTER ASSESSMENT

The emergence of 3D bioprinting prompts a need for a clearer
standard for patentable subject matter for nature-based products in general
and for 3D bioprinting specifically. The lack of guidance in the AIA’s
exemption of human organisms and the unclear markedly different
characteristics standard for patentable subject matter of nature-based
products, however, does not mean that either is incompatible with
patenting of 3D bioprinting technology. Rather, what is needed is a clearer
standard that provides inventors, the USPTO, and courts guidance on what
may be patentable subject matter as 3D bioprinting applications stress the
existing U.S. patent law regime.
Moreover, a clearer definition of what is or is not a human organism
will also help to delineate patentable subject matter. The silent amendment
to patentable subject matter in the AIA has added more confusion to what
is patentable subject matter in light of the emergence of 3D bioprinting.228
A clearer definition of what is not a human organism and what is not nature
are necessary for U.S. patent law to evolve and consider the advent of 3D
bioprinting.
Clarifications on patentable subject matter are particularly important
to enable inventors and patent practitioners to focus and expand upon their
research, development, and patent filing strategy. Because the law
governing the patentable subject matter requirements for years has been
unclear,229 and it appears that it will remain unclear in the near future
unless a new framework is adopted,230 it is possible that the validity of 3D
bioprinting patents will be challenged.231 Invalidity challenges to 3D
bioprinting inventions could stifle commercialization of 3D bioprinting
228. See supra notes 153–168 and accompanying text.
229. Sarah Smith, Claiming a Cell Reset Button: Induced Pluripotent Stem Cells and
Preparation Methods as Patentable Subject Matter, 56 B.C. L. REV. 1577, 1598 (2015) (suggesting
that there has been an ongoing struggle in the courts to identify the boundaries of patentable subject
matter, especially in the field of biotechnology); David O. Taylor, Amending Patent Eligibility, 50
U.C. DAVIS L. REV. 2149, 2154 (2017) (discussing that the Supreme Court has repeatedly failed to
identify a patent eligibility standard and noting that the Supreme Court has been obsessed with nonstatutory exceptions to patent eligibility, resulting in considerable confusion).
230. Efthimios Parasidis, A Uniform Framework for Patent Eligibility, 85 TUL. L. REV. 323,
329, 333 (2010) (proposing a decision tree algorithm that sets forth a series of questions on whether a
patent claim is precluded from patent eligibility in light of a lack of a comprehensive test for
determining patent eligible subject matter, which results in inconsistencies in district court rulings and
within the U.S. Patent & Trademark Office).
231. A defense to a claim for patent infringement is that the patent is invalid for not being
patentable subject matter or for another section of the Patent Act. While a patent is presumed valid
under 35 U.S.C. § 282, one method of attack on a patent is to examine whether what has been patented
is patentable subject matter through a motion to dismiss. Because an invalid claim cannot be infringed,
an accused infringer could be off the hook for the alleged infringement.
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inventions emerging from laboratories from becoming commercial
realities and having a positive impact on healthcare.
A.

Shortcomings of the Markedly Different Characteristics
Standard

The markedly different characteristics standard serves as a starting
point for evaluating the degree of alteration from a product of nature, but
it only compares an invention to the natural product from which it was
derived. This comparison is based on an ill-defined description of
structure, function, and/or properties, which are only described through a
list of examples provided in the USPTO’s Interim Guidance.232 None of
these examples consider 3D bioprinting. The markedly different
characteristics standard has three shortcomings that necessitate a new
standard, one that accounts for the advent and growth in 3D bioprinting.
First, the markedly different characteristics standard’s requirement
to contain only a new structure, function, and/or property from a product
found in nature would incentivize inventors to tailor inventions to comply
with this requirement. 3D bioprinting technology is increasingly able to
produce objects that resemble products of nature. In the case of 3D
bioprinted organs for transplantation, research and development towards
3D bioprinting and integrating nerves and vascularized tissues will
eventually yield exact replica organs for transplantation. If a court were to
utilize the USPTO’s markedly different characteristic standard to require
that a tissue created in a laboratory must have a slight degree of
dissimilarity to a naturally occurring tissue, then inventors would
purposefully try to create a 3D bioprinted tissue that possesses a slight
degree of dissimilarity. Requiring a markedly different characteristic
could compromise the effectiveness of 3D bioprinted material for medical
treatment for which replicated tissues or organs could be used. Tissues or
organs that are intentionally 3D bioprinted to be dissimilar to a slight
degree from a naturally occurring tissue or organ might not integrate well
into the human body, or might not have consistent 3D bioprinting
production, which could render medical treatment derived from 3D
bioprinting less effective than with near exact replication.
Second, 3D bioprinting technologies have advanced greatly since the
Chakrabarty233 decision in 1980 and have continued to expand rapidly
since the Myriad decision in 2013,234 and the technologies can more
closely replicate nature. Therefore, requiring an invention to hold
232. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134.
233. See generally Diamond v. Chakrabarty, 447 U.S. 303 (1980).
234. See generally Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107
(2013).
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markedly different characteristics than nature would reduce inventors’
incentive to innovate. This would be disadvantageous to innovation and
slow advancements towards producing replica organs, which could be
utilized for critical organ transplantation needs. Researchers and inventors
can more easily replicate naturally occurring products that share
characteristics with the invention at issue. Researchers’ time in attempting
to advance 3D bioprinting technology to create a beneficial 3D bioprinted
tissue or organ should be utilized to benefit the public, not to make a slight
modification to pass an unclear USPTO examination standard. A
requirement that an invention hold markedly different characteristics from
a product of nature causes disincentives to innovation in 3D bioprinting.
Society should incentivize 3D bioprinting researchers to create inventions
that mimic products of nature because such 3D bioprinting inventions have
substantial healthcare benefits and utility.
Third, a requirement that an invention hold markedly different
characteristics than nature is a greater legal challenge to patentable subject
matter today than it was during the time of the Chakrabarty235 decision in
1980 and even the recent Myriad236 decision in 2013. Due to the rapid
technological progress of 3D bioprinting in recent years, inventors can
more easily produce 3D bioprinted materials that share characteristics with
products of nature. Inventors and patent practitioners would have to spend
substantially more time and effort in distinguishing 3D bioprinting
inventions from products of nature now than in the past. The law has not
kept up with rapid advancements in 3D printing, let alone with 3D
bioprinting. It would cost society more in the form of time and energy of
inventors and patent practitioners drafting and prosecuting patent
applications to overcome the markedly different characteristics standard
than it would if there were a clearer and more flexible standard for 3D
bioprinting inventions. A clearer standard would allow inventors to
foresee whether their inventions are patentable subject matter.
These reasons necessitate a clearer standard to assess patentable
subject matter for nature based products, such as those enabled by 3D
bioprinting. The lack of clear boundaries in this area of patent law leaves
unclear whether 3D bioprinting inventions are patentable subject matter.
A clearer standard for nature-based biotechnologies in general would also
assist USPTO Examiners and judges in assessing whether 3D bioprinting
inventions are patentable subject matter.

235. See generally Diamond, 447 U.S. 303.
236. See generally Myriad Genetics, 133 S. Ct. 2107.
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Proposed Mixed-Scanned-Transformed (MST) Standard

The markedly different characteristics standard focuses on the extent
of physical differences between modified items and their naturally
occurring counterparts. The words used in this standard came from the
Chakrabarty237 case of 1980, and hence, are based in an era tied to old
technologies. The standard used for patentable subject matter for naturebased products should not be based on what biotechnologies have been,
but instead should be broadly concerned with what biological
technologies, such as 3D bioprinting, could be in the future. Moreover, the
markedly different characteristics standard for patentable subject matter
has been vague to the point where it could function as a categorical
prohibition of some inventions.
Because the markedly different characteristics standard has
shortcomings, and because courts have yet to utilize this standard for
assessing patentable subject matter for 3D bioprinting, a clearer standard
would encourage clarity in patent law. A clearer standard that is flexible
enough to capture unknown technologies and avoid limitations tied to
historical considerations would need to be forward looking and inclusive.
A clearer standard that articulates a continuum of change from nature
would allow a court the flexibility to construe change from nature as it
deems proper for the circumstances. Such a new standard would also need
to provide public notice with specificity to inventors regarding what
inventions would qualify as patentable subject matter.
This Article proposes a new standard, a Mixed-ScannedTransformed (MST) standard, for nature-based products to supplement the
Interim Guidance.238 As a supplement, the MST standard would be an
additional step in the examination of nature-based products. This new
MST standard would encourage 3D bioprinting inventions and ensure that
patent incentives are coextensive with the development of emerging 3D
printing technologies. The proposed, supplemented MST standard is
consistent with older standards that emphasize purification, isolation, and
markedly different characteristics of nature-based products but is not
limited to only physical transformation based on chemical processes
covered by the older tests on nature-based products. The proposed MST
standard would also encompass other commentators’ suggestions to
compare structural and molecular properties239 in assessing patentable
subject matter for nature-based products, as well as account for Bio-CAD
files as patentable subject matter. The recognition that Bio-CAD files,
237. See Diamond, 447 U.S. at 309.
238. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134.
239. See Samantak Ghosh, Gene Patents: Balancing the Myriad Issues Concerning the Patenting
Natural Products, 27 BERKELEY TECH. L.J. 241 (2012).

50

Seattle University Law Review

[Vol. 41:1

whether unmodified or modified, constitute patentable subject matter
under the proposed MST standard means that additional 3D bioprinting
inventions may qualify for patent protection.
In this proposed, supplemental “Mixed-Scanned-Transformed”
standard, the word “mixed” refers to combining elements, which may
include natural with non-natural elements, such as a product of nature with
a man-made material. The word “scanned” refers to converting a physical
object into a digital representation, such as in a medical image. The word
“transformed” refers to making changes to a CAD file digitally, such as in
a digital transformation through a computer, or to making changes
physically, such as changing physical properties through a chemical
process. Thus, transformed could indicate a change from physical to
digital, or from digital to physical. The proposed, supplemental MST
standard considers a product that is mixed, scanned, or transformed to
qualify as patentable subject matter; it does not necessarily require a
product to be mixed, scanned, and transformed to be patent eligible. For
example, the MST standard would consider each of the following
patentable subject matters: (1) mixed artificial and human biological
materials, (2) scanned objects in a Bio-CAD file, and (3) information or
data content that is transformed from the digital realm to the physical
realm in the form of a product or material, or alternatively, a product or
material that is transformed from the physical realm to the digital into
information or data content.
There are two key differences between the markedly different
characteristics standard and this newly proposed, supplemental MST
standard. First, the Interim Guidance refers to markedly different
characteristics being a change in structure, function, and/or properties. 240
But such a change does not account for man-made materials that mimic
nature. For example, there would be no differentiation between a synthetic
material introduced into a 3D bioprinting process that mimics nature and
a natural material that is 3D bioprinted that similarly mimics nature. In
both cases, the structure, function, and/or properties would be the same,
but the markedly different characteristics standard would not account for
the fact that one is based on a product of nature and another a mixed
synthetic and natural product. The markedly different characteristics
standard has not been able to keep pace with 3D bioprinting’s ability to
mix synthetic and natural materials.
Second, the markedly different characteristics standard presented in
the Interim Guidance implies a change in structure, function, and/or
properties either as a chemical change or physical change based on a
240. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134.
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chemical process.241 Would a change from a physical object to a digital
object, in the form of a MRI or CT scan into a Bio-CAD file, be considered
a markedly different characteristic in structure, function, and/or property?
Would a Bio-CAD file modification, which would demonstrate a change
digitally in structure, function, and/or properties to a 3D bioprinted object
a press of a button away be considered markedly different? The intention
of the Court in the Myriad242 case does not account for the blurred
physical-digital and blurred living and nonliving worlds of 3D bioprinting.
A patentable subject matter standard, such as the proposed, supplementtal
MST standard, will consider Bio-CAD files equally important to other 3D
bioprinting inventions, such as the 3D bioprinter and the 3D bioprinted
material.
Accordingly, the proposed, supplemental MST standard would
enable a 3D bioprinting inventor to provide reasoning to overcome
disqualifications following the markedly different standard and
significantly more inquiry, allowing the inventor to present arguments that
describe the invention as mixed, scanned, or transformed. By
supplementing the USPTO examination of nature-based products, this
new examination step would give a patentee an opportunity to demonstrate
that the invention has been mixed, scanned, or transformed. The proposed,
supplemental MST standard would be adequately flexible to cover a
continuum of degree of changes from nature and provide a sliding scale
approach to assessing patentable subject matter for nature-based products.
C.

Responding to Potential Criticisms of the MST Standard

This Article anticipates that some will critique the proposed,
supplemental MST standard. Criticism of the proposed, supplemental
MST standard will likely center on three main arguments: 1) the proposed
standard may seem to violate the uniformity principle in patent law of not
favoring certain technologies; 2) some may question whether the cloning
decision in the case In re Roslin Institute243 would argue against patent
eligibility of 3D bioprinting inventions; and 3) legal scholars may question
whether a clearer standard for patentable subject matter for nature-based
products incentivizes inventors. There have been many discussions on
whether patents incentivize innovation and that is outside the scope of this
Article. Instead, the first concern regarding the uniformity principle and
the second concern regarding cloning are legitimate issues that would need
to be addressed by Congress and the USPTO before implementing the

241. Id.
242. See Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 (2013).
243. In re Roslin Institute (Edinburgh), 750 F.3d 1333, 1334 (Fed. Cir. 2014).
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proposed, supplemental MST standard in the examination of nature-based
patents, such as those of 3D bioprinting, at the USPTO.
1.

Replying to Concerns on Uniform Treatment of Technologies in
U.S. Patent Law

An improvement to the patentable subject matter standard for naturebased products should be the objective of each of the inventors who file
patent applications, the USPTO and patent examiners, and the federal
courts. A challenge with developing a clearer standard for
biotechnological inventions, however, is the notion that U.S. patent law
does not differentiate among technologies. The notion that the U.S. patent
system operates as a uniform system that applies neutrally to all inventions
has been contested by many commentators. Professors Dan Burk and Mark
Lemley have suggested that there is an increasing divergence between
patent law and the application of patent law to different industries,
particularly with biotechnology.244 Another commentator has suggested
that some provisions of the AIA are specific to certain types of inventions
demonstrating a number of exceptions to technology neutrality.245
This Article does not debate whether sector-specific patent principles
are merited or imprudent. The discussion herein does not delve into
whether the patent system should operate as a uniform and neutral system
to all inventions. Instead, this Article recognizes that the AIA has
determined that there are limits to patenting human organisms. This
limitation demonstrates that the congressional intent in the patent system
is to have a different standard for patentable subject matter. Thus, there is
impetus for modifying the U.S. patent system to work in a non-neutral
fashion to meet the needs of specific industries where human organisms
are at issue. The salient distinction of human organisms implies that the
U.S. patent system may need to be tailored to reflect the needs of distinct
technology sectors, such as 3D bioprinting, where inventions concerning
human organisms are available and proliferating.
The proposed, supplemental MST standard more clearly addresses
the rationale behind requiring that a nature-based invention possess a
markedly different characteristic from the natural product from which it
was derived. This Article suggests that the proposed, supplemental MST
244. Dan L. Burk & Mark A. Lemley, Is Patent Law Technology-Specific?, 17 BERKELEY TECH
L.J. 1155, 1156–95 (2002) (suggesting there is variance in patent law because of the Person Having
Ordinary Skill in the Art standard (PHOSITA), which generates a technology-specific body of patent
law).
245. JOHN R. THOMAS, CONG. RES. SERV., R43264, TAILORING THE PATENT SYSTEM FOR
SPECIFIC INDUSTRIES 7-5700, at 1 (2015) (noting that the AIA has limited patents on tax strategies and
human organisms, has created proceedings that apply exclusively to patents pertaining to business
methods, and prioritizes examination of applications important to national security).
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standard will follow patent law’s uniformity principle, which requires that
all inventions be assessed equally regardless of technology specificity
because it supplements the Interim Guidance. In other words, the MST
assessment is simply an additional new Step 3 for the Interim Guidance246
and would only be applicable in the case an invention does not qualify
under Step 2A’s markedly different characteristics standard and under
Step 2B’s significantly more inquiry. This new Step 3 adds more clarity,
and perhaps more complexity, to the USPTO’s existing examination
procedure, but it does not attempt to differentiate between technologies.
Only if an invention does not qualify under Step 2A and Step 2B would
such an invention even be considered under the newly proposed,
supplemental MST standard. This Article argues that the proposed,
supplemental MST standard is not meant to be a filtering and separating
mechanism between various technologies, but instead, is meant to be a
better means for delineating a boundary for determining what may or may
not be patentable subject matter.
2.

Distinguishing Cloning with Dolly the Sheep

In In re Roslin Institute, the court held that the patent claims directed
to Dolly the Sheep247 were not patent eligible because a cloned animal “is
an exact genetic replica of another [animal] and does not possess
‘markedly different characteristics’ from any farm animals found in
nature.”248 Dolly the Sheep had nucleic genetic material that was a copy
of the adult from which she was cloned, and the word “clone” in the patent
claims indicated an exact genetic identity.249 The patentee Roslin Institute
had argued that Dolly the Sheep had phenotypic differences and had
differences in mitochondrial DNA.250 Despite the patentee’s arguments
that the sheep did have phenotypic or mitochondrial differences, the
Federal Circuit held that such differences were not claimed in the patent
246. See 2014 INTERIM GUIDANCE ON PATENT SUBJECT MATTER ELIGIBILITY, supra note 134.
247. U.S. Patent Application No. 09/225, 233 claimed the cloned animals included: “155. A liveborn clone of a pre-existing, non-embryonic, donor mammal, wherein the mammal is selected from
cattle, sheep, pigs, and goats. 164. The clone of any claims 155-159, wherein the donor mammal is
non-foetal).” In re Roslin Institute (Edinburgh), 750 F.3d at 1335.
248. Id. at 1337 (citation omitted) (holding that the first mammal ever cloned from an adult
somatic cell, Dolly the Sheep, was ineligible for patent protection as claimed because it constituted a
natural phenomenon that did not possess markedly different characteristics than found in nature
because the cloned sheep was an exact copy of the mammal from which the somatic cell was taken).
249.
Jason
Rantanen,
Claiming
Clones,
PATENTLY-O
(May
8,
2014),
https://patentlyo.com/patent/2014/05/claiming-clones.html [https://perma.cc/UJF2-VNP8].
250. Donald Zuhn, Dolly the Sheep Not Patent Eligible Subject Matter, PATENT DOCS (May 8,
2014), http://www.patentdocs.org/2014/05/in-re-roslin-institute-fed-cir-2014.html [https://perma.cc/
E64H-XCF4] (discussing that the Roslin Institute had argued clones should be patent eligible because
the DNA originated from the donor oocyte rather than the donor nucleus).
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claims, which were drafted in terms of genetic identity.251 The court
appeared to ignore that a clone would inherently have phenotypic
differences due to its development in different environmental conditions
than the donor.
One argument to distinguish 3D bioprinting from Dolly the Sheep is
based on inept patent claims drafting. The patent claims directed to Dolly
the Sheep failed to distinguish cloning in any way in the patent claims or
the patent specification.252 The court appeared to leave the door slightly
ajar for patent eligibility of cloned sheep in stating:
There is nothing in the claims, or even in the specification, that
suggests that the clones are distinct in any relevant way from the
donor animals of which they are copies. The clones are defined in
terms of the identity of their nuclear DNA to that of the donor
mammals . . . the claims do not describe clones that have markedly
different characteristics from the donor animals of which they are
copies.253
The court’s reasoning suggests that the unique features of the
claimed sheep were not indicated in the patent claims, and therefore, the
claims did not establish any differences from nature. The court seemed to
indicate that better patent claims drafting could have highlighted the
differences from nature and, therefore, may have enabled patent eligibility
consideration of features that may have been markedly different from
nature. In essence, the court seemed to implicitly interpret the claims in a
manner least favorable to the patentee, whereas the USPTO’s patent
examiners would be charged with the broadest reasonable interpretation254
of such patent claims, which means the patent claims may have been
patentable subject matter.
A second argument to distinguish 3D bioprinting from Dolly the
Sheep is based on biology. Dolly the Sheep had shorter telomeres than
other animals of the same age.255 Therefore, Dolly would not be considered
an exact replica of her donor and, hence, would have the necessary
markedly different characteristics to be considered patentable subject
251. See Rantanen, supra note 249.
252. See In re Roslin Institute (Edinburgh), 750 F.3d at 1337.
253. See id. at 1339.
254. MPEP, supra note 65, § 2111 (specifying that during patent examination, patent claims must
be given their broadest reasonable interpretation consistent with the specification, which is based on
the Federal Circuit’s en banc decision in Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005)).
255. Mercedes K. Meyer, Alice Sat on Prometheus and Met Dolly the Sheep Who Said
Baaaaaahhhh to Myriad, AM. INTELL. PROP. L. ASS’N (Oct. 22, 2014),
http://studylib.net/doc/9811309/myriad—-american-intellectual-property-law-association
[https://perma.cc/KH9D-SDLL] (indicating that telomeres, which are pieces of DNA that protect ends
of chromosomes, shorten as cells divide and therefore considered as a measure of ageing of cells).
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matter. This subtle difference of shorter telomeres, which was overlooked
by the court and resulted in Dolly the Sheep’s early death, would only have
occurred in older sheep.256 Such a biological example is a type of
difference that would have yielded markedly different characteristics.
Because cloning does not produce an exact replica biologically, even if the
patent claims attempt to claim as such, the inherent biological limitations
of cloning would produce markedly different characteristics. A wise patent
practitioner would attempt to capture such inherent biological differences
in a patent claim. Similarly, any such biological differences promoted by
3D bioprinting technology would yield markedly different characteristics
to result in patentable subject matter. 3D bioprinting technology itself has
technological limitations that inherently would yield similar biological
differences. Moreover, 3D bioprinting technology would enable precision
design to create engineered differences in biology, and such a design
choice would yield markedly different characteristics than what is found
in nature.
V.

SOUND POLICY FAVORS CLEARER PUBLIC NOTICE OF 3D
BIOPRINTING

Throughout U.S. history, patentable subject matter doctrine has been
flexible and robust by adapting to new technologies in diverse
industries.257 Each time there is an emerging technology, the question of
patent eligibility of a category of inventions is, at a fundamental level, a
question about whether the benefits outweigh the costs that arise form
granting patents to that category of invention.258
The utilitarian point of view of the patent system259 would support
favoring the benefits of a new category to make available to the public new
and useful inventions that would not otherwise have been available. To
achieve this goal, a standard for determining patent eligibility of a new
category would need to encourage (1) creation of inventions, (2) disclosure
of inventions to the public, and (3) further development and
commercialization of inventions.260 This Article contends that patentable
256. Id.
257. See generally David J. Kappos et al., A Technological Contribution Requirement for
Patentable Subject Matter: Supreme Court Precedent and Policy, 6 NW. J. TECH. & INTELL. PROP.
152 (2008).
258. Yuqing Cui, A Quantitative Approach to Determining Patentable Subject Matter (May
2015) (unpublished research paper, Harvard Law School) (on file with author).
259. See generally David S. Olson, Taking the Utilitarian Basis for Patent Law Seriously: The
Case for Restricting Patentable Subject Matter, 82 TEMP. L. REV. 181 (2009) (suggesting that the U.S.
Constitution and patent law casebooks indicate that our patent system incentivizes the production and
distribution of innovation).
260. See John M. Golden, Principles for Patent Remedies, 88 TEX. L. REV. 505, 510–11 (2010).
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subject matter standards for nature-based products should respond with a
more bright-line standard. By redrawing the patentable subject matter
boundaries for nature-based products, new discoveries of 3D bioprinting
materials and the Bio-CAD files that digitally represent them will promote
clearer patenting. This will not necessarily lead to more patents being filed
for 3D bioprinting inventions, but instead will lead to less ambiguity
regarding what may be patentable in this emerging industry.
A clearer standard for patentable subject matter for nature-based
products and for 3D bioprinting inventions would provide a clearer “notice
function” and reduce the risks of disputes and litigation.261 A clearer
boundary of what may be considered patentable subject matter has an
economic value to inventors for determining when to pursue patents, to
the USPTO for its role as an agency in the examination of patent
applications, and to the public for providing notice on what may be
patentable.262 The adoption of a more bright-line standard would give 3D
bioprinting researchers a better indication of whether their inventions are
patentable subject matter. This, in turn, would allow them to focus on
improving 3D bioprinting, rather than patent attorneys and patent agents
focusing on cleverly drafting patent claims263 in an attempt to qualify
inventions under the markedly different characteristics standard.
Sound public policy favors that 3D bioprinting not be subject to
ambiguous patent law standards, which can produce wasteful efforts to
evaluate and enforce patent rights. Ambiguous patent law standards can
lead to curtailment of invention activities due to threats of patent invalidity
challenges and patent litigation enforcement.264 Rather than have the scope
of 3D bioprinting patent rights be rendered obscured by uncertain
patentable subject matter standards, more clarification and consistency of
patentable subject matter would provide the impetus for development of
261. See JAMES BESSEN & MICHAEL J. MEURER, PATENT FAILURE: HOW JUDGES,
BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT RISK 1, 6–10 (2008) (comparing patents to
tangible property, each providing partial use and ownership rights and incentives to invest in
acquisition, development, and maintenance; further stating that property systems fail to provide
incentives when their validity is uncertain, and then when rights are highly fragmented or boundaries
of rights are not clear and predictable, negotiations become cost prohibitive).
262. Alan Marco et al., Patent Claims and Patent Scope 5 (USPTO, Economic Working Paper
No. 2016-04, 2016), https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964 (discussing that
patent boundaries that are clearly defined to the benefit of the patent owner, the courts, third parties,
and the public at large, give inventors and investors the confidence in taking the risk necessary to
launch products and start businesses, as well as give the public at large the benefit of knowing precise
boundaries of an exclusionary right).
263. See generally Tun-Jen Chiang, Forcing Patent Claims, 113 MICH. L. REV. 513 (2015)
(suggesting that because patent claims define the scope of a limited monopoly right, patentees subtly
slant the patent claim’s language in a way that aggrandizes their patent rights).
264. Keith E. Witek, Developing a Comprehensive Software Claim Drafting Strategy for U.S.
Software Patents, 11 BERKELEY TECH. L.J. 363, 366–67 (1996).
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3D bioprinting inventions. A lack of clarity around the patentable subject
matter standard would impose a disincentive to investing in emerging
technologies such as 3D bioprinting. Moreover, patent quality would
deteriorate when patent boundaries, such as those for patentable subject
matter, are difficult to determine, thereby further causing societal loss.
Several relevant stakeholders would benefit from a clearer standard.
A more bright-line standard for 3D bioprinting would be highly important
for administrative, judicial, and private law contexts, as well as for overall
public benefits. In an administrative context, clearer 3D bioprinting
patentable subject matter would benefit inventors and USPTO examiners.
First, 3D bioprinting inventors need a more bright-line standard to shape
their patent claims so as to include the necessary features to qualify for
patents. Second, USPTO patent examiners need a clearer standard to
ensure consistency in accepting or rejecting patent claims covering new
3D bioprinting inventions. There will be reduced patent quality if USPTO
patent examiners have difficulty properly reviewing patent applications.
Third, in a judicial context, federal courts called upon to enforce
patents covering 3D bioprinting inventions will need clearer standards to
determine, which, if any, 3D bioprinting patent claims are valid and
enforceable. These judicial assessments of patent invalidity due to nonpatentable subject matter will not only determine monetary and injunctive
relief but will also indicate to potential infringers what patent licenses are
necessary to use inventions or develop design-around patenting strategies.
Thus, the definiteness of a 3D bioprinting standard affects interpretation
by an initial court, inevitably affecting downstream litigation and licensing
settlement negotiations.
Fourth, in a private law context, investors, such as angel investors or
venture capitalists, need more clarity concerning patentable subject matter
to shape investments in nascent, high-growth, startup companies that will
develop and commercialize 3D bioprinting technologies. There will be
greater societal costs if boundaries are not adequately delineated, such as
investors needing to seek expensive legal opinions about patent
boundaries and the scope of patent rights.265 3D bioprinting startups, such
as Organovo266 and Poietis,267 which have engaged in joint development
agreements and partnerships with established companies, need clearer
standards to assess the validity of 3D bioprinting patents as they transfer
265. See BESSEN & MEURER, supra note 261 (discussing that poor property notice would cause
investors to more strongly consider their risk of being sued for patent infringement over the reward
they might reap from owning and commercializing patents, and therefore without clear boundary
markers, investors may not attempt to clear the necessary rights before investing).
266. See Organovo Investor Presentation, supra note 49.
267. See Cosimo, supra note 51.
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their patent rights while also scaling their laboratory results with existing
manufacturing and supply chains.
Fifth, established biomedical and biotech corporations will not only
consider the validity of startups’ patents in partnership agreements but will
also consider whether to channel their own resources and budgets towards
3D bioprinting internal research and development and patenting efforts. In
sum, private law transactions involving activities or products dependent
on 3D bioprinting patents need to be able to predict whether the patents
involved will be enforceable or an impediment to commercial strategies.
Sixth, and perhaps most importantly, organ transplantation
hopefuls268 and burn victims269 are awaiting healthcare innovations for
their medical needs. Slowing the rate of 3D bioprinting patenting will only
prolong the shortage of organ transplantation and burn victim treatments.
Patentable subject matter standards not only have an important role in
patent law but also in health law. The standard for patentable subject
matter is not only a gatekeeper function for patent law, but also indirectly
serves as a gatekeeper for healthcare innovations. In essence, changes in
patentable subject matter affect whether a patent will be valid and whether
inventions will be commercialized. In sum, a broad view of patentable
subject matter for 3D bioprinting does not automatically mean there will
be a large number of 3D bioprinting patents. Rather, recognizing that 3D
bioprinting innovations constitute patentable subject matter will lead to
heightened patenting, thereby enabling easier patent examination by the
USPTO, clearer and higher quality issued patents, and quicker-tocommercialize encompassing technologies. The promise and incentive of
patent rewards will encourage 3D bioprinting innovation and invention
concerning patentable subject matter. The choice of which categories of
3D inventions to allow into the patentable subject matter boundaries is
essentially a choice of which healthcare innovations the patent system
should promote. A more bright-line approach to patentable subject matter
will ensure that patent incentives will coexist with the scope of potentially
beneficial associated public healthcare solutions.
The demarcation of patentable subject matter boundaries for an
emerging technology is not an easy task.270 This Article provides a first
268. See Harbaugh, supra note 42.
269. Illene Wolff, The Next Step for Bioprinting: 3D Printing Skin, ADVANCED
MANUFACTURING (Mar. 7, 2016), http://advancedmanufacturing.org/next-step-bioprinting-3dprinting-skin/ [https://perma.cc/8GHB-CQGE] (stating that there are 11 million burns annually
worldwide that need medical attention according to the World Health Organization, and that in the
U.S. in 2015, 486,000 burn injuries received medical treatment according to the American Burn
Association).
270. See BESSEN, supra note 261 (describing that unlike tangible property, which is a rival good
because only one person can use it at a time, more than one person can use an invention, and therefore,
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step towards providing more clarity around the patentable subject matter
boundaries for emerging 3D bioprinting technologies. A clearer standard
for patentable subject matter will not necessarily mean more patenting of
3D bioprinting inventions, but will help avoid downstream, costly disputes
and lead to more rapid growth of the emerging 3D bioprinting industry.
CONCLUSION
Inventors are combining principles of 3D printing with synthetic
biology to replace damaged tissues, restore malfunctioning organs, permit
organ transplantation, repair skin burns, and create wearable microbiomes.
This new phenomenon of 3D bioprinting blurs the digital, physical, living,
and nonliving worlds, and challenges U.S. patent law in the patentable
subject matter doctrine. The transformative technology of 3D bioprinting
magnifies the unclear markedly different characteristics standard and
human organism exception in U.S. patent law. These shortcomings require
that U.S. patent law respond with a more bright-line standard to promote
3D bioprinting inventive activity. A proposed supplement to the current
USPTO examination procedure would lead to clearer 3D bioprinting
patenting and promote administrative, judicial, and private law
efficiencies and healthcare benefits.

while patent law shares some doctrinal features in common with tangible property, the boundaries of
patent law doctrines are tougher to define than those of real property because multiple inventors may
have rights to an invention that could have many different facets).

